HEALTHCARE SERVICES GROUP INC, 10-K filed on 2/14/2025
Annual Report
v3.25.0.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 12, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 0-12015    
Entity Registrant Name HEALTHCARE SERVICES GROUP, INC.    
Entity Incorporation, State Code PA    
I.R.S. Employer Identification No. 23-2018365    
Entity Address, Address Line One 3220 Tillman Drive    
Entity Address, Address Line Two Suite 300    
Entity Address, City or Town Bensalem    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19020    
City Area Code 215    
Local Phone Number 639-4274    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol HCSG    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 620
Entity Common Stock, Shares Outstanding   73,487,743  
Documents Incorporated by Reference
Portions of the Definitive Proxy Statement for the registrant’s 2025 Annual Meeting of Shareholders (the “Proxy Statement”), to be filed within 120 days of the end of the fiscal year ended December 31, 2024, are incorporated by reference in Part III hereof. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.
    
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000731012    
v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Auditor Information [Abstract]  
Auditor Name GRANT THORNTON LLP
Auditor Location Philadelphia, Pennsylvania
Auditor Firm ID 248
v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 56,776 $ 54,330
Restricted cash equivalents 3,355 0
Marketable securities, at fair value 50,535 93,131
Restricted marketable securities, at fair value 25,105 0
Accounts receivable, less allowance for doubtful accounts of $87,520 and $80,817 as of December 31, 2024 and 2023, respectively 330,907 344,864
Notes receivable — short–term portion, less allowance for doubtful accounts of $10,372 and $6,433 as of December 31, 2024 and 2023, respectively 51,429 38,645
Inventories and supplies 16,749 18,479
Prepaid expenses and other assets 21,796 22,247
Total current assets 556,652 571,696
Property and equipment, net 28,198 28,774
Goodwill 75,529 75,529
Other intangible assets, less accumulated amortization of $39,242 and $36,557 as of December 31, 2024 and 2023, respectively 9,442 12,127
Notes receivable — long–term portion, less allowance for doubtful accounts of $2,890 and $4,449 as of December 31, 2024 and 2023, respectively 41,054 24,832
Deferred compensation funding, at fair value 49,639 40,812
Deferred tax assets 38,170 35,226
Other long-term assets 4,088 1,656
Total assets 802,772 790,652
Current liabilities:    
Accounts payable 81,147 83,224
Accrued payroll and related taxes 51,579 56,142
Other accrued expenses and current liabilities 24,783 21,179
Borrowings under line of credit 0 25,000
Income taxes payable 8,391 7,201
Deferred compensation liability — short-term 1,499 1,501
Accrued insurance claims 25,148 22,681
Total current liabilities 192,547 216,928
Accrued insurance claims — long-term 51,869 61,697
Deferred compensation liability — long-term 50,011 41,186
Lease liability — long-term 8,033 11,235
Other long-term liabilities 385 2,990
Commitments and contingencies (Note 14)
STOCKHOLDERS’ EQUITY:    
Common stock, $0.01 par value; 200,000 and 100,000 shares authorized as of December 31, 2024 and 2023, respectively; 76,533 and 76,329 shares issued, and 73,203 and 73,341 shares outstanding as of December 31, 2024 and 2023, respectively 765 763
Additional paid-in capital 318,363 310,436
Retained earnings 224,556 185,010
Accumulated other comprehensive loss, net of taxes (2,317) (1,844)
Common stock in treasury, at cost, 3,330 and 2,988 shares as of December 31, 2024 and 2023, respectively (41,440) (37,749)
Total stockholders’ equity 499,927 456,616
Total liabilities and stockholders’ equity $ 802,772 $ 790,652
Common stock, authorized (in shares) 200,000,000 100,000,000
v3.25.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts, current $ 87,520 $ 80,817
Allowance for doubtful accounts, notes receivable — short–term portion 10,372 6,433
Accumulated amortization of other intangible assets 39,242 36,557
Allowance for doubtful accounts, noncurrent $ 2,890 $ 4,449
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 200,000,000 100,000,000
Common stock, issued (in shares) 76,533,000 76,329,000
Common stock, outstanding (in shares) 73,203,000 73,341,000
Common stock in treasury (in shares) 3,330,000 2,988,000
v3.25.0.1
Consolidated Statements of Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenues $ 1,715,682 $ 1,671,389 $ 1,690,176
Operating costs and expenses:      
Costs of services provided 1,487,592 1,456,643 1,496,865
Selling, general and administrative expense 183,060 166,772 140,344
Other income (expense):      
Investment and other income (loss), net 14,349 12,938 (5,427)
Interest expense (6,438) (7,856) (2,987)
Income before taxes 52,941 53,056 44,553
Income tax provision 13,470 14,670 10,310
Net income $ 39,471 $ 38,386 $ 34,243
Per share data:      
Basic earnings per common share (in dollars per share) $ 0.54 $ 0.52 $ 0.46
Diluted earnings per common share (in dollars per share) $ 0.53 $ 0.52 $ 0.46
Weighted average number of common shares outstanding:      
Basic (in shares) 73,754 74,288 74,336
Diluted (in shares) 73,988 74,340 74,351
Comprehensive income:      
Net income $ 39,471 $ 38,386 $ 34,243
Other comprehensive (loss) income      
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes (473) 1,633 (7,477)
Total comprehensive income $ 38,998 $ 40,019 $ 26,766
v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net income $ 39,471 $ 38,386 $ 34,243
Adjustments to reconcile net income to net cash provided by (used in) operating activities      
Depreciation and amortization 14,585 14,344 15,316
Bad debt provision 46,760 35,604 31,969
Deferred income taxes (2,944) (4,820) 4,907
Share-based compensation expense 9,165 8,985 9,214
Amortization of premium on marketable securities 1,504 2,144 2,219
Unrealized gain on deferred compensation fund investments (8,168) (6,645) 9,422
Changes in other long-term liabilities (564) (1,154) (2,353)
Net loss on disposals of property and equipment 654 818 1,138
Share of losses from equity method investment 532 0 0
Changes in operating assets and liabilities:      
Accounts and notes receivable (61,809) (74,559) (78,707)
Inventories and supplies 1,731 2,685 4,851
Prepaid expenses and other assets 704 12,750 9,935
Deferred compensation funding (534) (674) 3,913
Accounts payable and other accrued expenses (9,741) 7,430 (13,748)
Accrued payroll, accrued and withheld payroll taxes (3,573) 4,186 (23,859)
Income taxes payable 1,190 572 2,184
Accrued insurance claims (7,362) (4,329) (687)
Deferred compensation liability 9,201 7,775 (18,124)
Net cash provided by (used in) operating activities 30,802 43,498 (8,167)
Cash flows from investing activities:      
Disposals of property and equipment 211 121 393
Additions to property and equipment (6,336) (5,406) (5,210)
Acquisition of equity method investment (2,750) 0 0
Purchases of marketable securities (52,090) 0 (2,875)
Sales of marketable securities 67,012 1,992 10,386
Cash paid for acquisitions 0 0 (114)
Net cash provided by (used in) investing activities 6,047 (3,293) 2,580
Cash flows from financing activities:      
Dividends paid 0 0 (63,373)
Reissuance of treasury stock pursuant to Dividend Reinvestment Plan 0 0 106
Proceeds from the exercise of stock options 0 0 410
Purchases of treasury stock (5,018) (11,283) 0
(Repayments of) proceeds from short-term borrowings (25,000) 0 25,000
Payments of statutory withholding on net issuance of restricted stock units (1,030) (871) (1,071)
Net cash used in financing activities (31,048) (12,154) (38,928)
Net increase (decrease) in cash, cash equivalents, and restricted cash equivalents 5,801 28,051 (44,515)
Cash, cash equivalents and restricted cash equivalents at beginning of the period 54,330 26,279 70,794
Cash, cash equivalents and restricted cash equivalents at end of the period 60,131 54,330 26,279
Supplementary cash flow information:      
Cash paid for interest 6,491 7,809 2,822
Cash paid for income taxes $ 15,232 $ 5,585 $ 3,309
v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income, net of Taxes
Retained Earnings
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021   76,009        
Accumulated other comprehensive (loss) income — beginning balance at Dec. 31, 2021 $ 445,171 $ 760 $ 294,124 $ 4,000 $ 176,451 $ (30,164)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 34,243       34,243  
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes (7,477)     (7,477)    
Shares issued in connection with equity incentive plans, net of taxes (in shares)   148        
Shares issued in connection with equity incentive plans, net of taxes (661) $ 2 (663)      
Share-based compensation expense 9,044   9,044      
Shares issued for Deferred Compensation Plan, net 374   (634)     1,008
Shares issued for Employee Stock Purchase Plan 1,512   368     1,144
Dividends paid and accrued (64,092)       (64,092)  
Shares issued pursuant to Dividend Reinvestment Plan 106   6     100
Other (in shares)   4        
Other 59   59      
Ending balance (in shares) at Dec. 31, 2022   76,161        
Accumulated other comprehensive loss — ending balance at Dec. 31, 2022 418,279 $ 762 302,304 (3,477) 146,602 (27,912)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 38,386       38,386  
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes 1,633     1,633    
Shares issued in connection with equity incentive plans, net of taxes (in shares)   167        
Shares issued in connection with equity incentive plans, net of taxes (870) $ 1 (871)      
Share-based compensation expense 8,836   8,836      
Purchases of treasury stock (11,283)         (11,283)
Shares issued for Deferred Compensation Plan, net 470   298     172
Shares issued for Employee Stock Purchase Plan 1,135   (139)     1,274
Other (in shares)   1        
Other $ 30   8   22  
Ending balance (in shares) at Dec. 31, 2023 73,341 76,329        
Accumulated other comprehensive loss — ending balance at Dec. 31, 2023 $ 456,616 $ 763 310,436 (1,844) 185,010 (37,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 39,471       39,471  
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes (473)     (473)    
Shares issued in connection with equity incentive plans, net of taxes (in shares)   204        
Shares issued in connection with equity incentive plans, net of taxes (1,030) $ 2 (1,032)      
Share-based compensation expense 8,919   8,919      
Purchases of treasury stock (5,018)         (5,018)
Shares issued for Deferred Compensation Plan, net 378   256     122
Shares issued for Employee Stock Purchase Plan 989   (216)     1,205
Other $ 75       75  
Ending balance (in shares) at Dec. 31, 2024 73,203 76,533        
Accumulated other comprehensive loss — ending balance at Dec. 31, 2024 $ 499,927 $ 765 $ 318,363 $ (2,317) $ 224,556 $ (41,440)
v3.25.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical)
 12 Months Ended
Dec. 31, 2022
$ / shares
Statement of Stockholders' Equity [Abstract]  
Cash dividend paid per common share (in dollars per share) $ 0.86
v3.25.0.1
Description of Business and Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Description of Business and Significant Accounting Policies
Note 1 — Description of Business and Significant Accounting Policies

Nature of Operations

Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments of the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, they are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs.

The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.

The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”).

Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility.

Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs.

Principles of Consolidation

The financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the SEC, specifically Regulation S-X and the instructions to Form 10-K. Unless otherwise indicated, all references to years are to the Company’s fiscal year, which ends on December 31.

The accompanying Consolidated Financial Statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates in Financial Statements

In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.

Fair Value of Financial Instruments

The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy.
Assets and liabilities are classified within the fair value hierarchy based on the lowest level (least observable) input that is significant to the measurement in its entirety.

While unobservable inputs reflect the Company’s market assumptions, preference is given to observable inputs. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices for identical instruments in active markets;
Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and
Level 3 – Significant inputs to the valuation model are unobservable

The Company’s financial instruments that are measured at fair value on a recurring basis consist of marketable securities and the deferred compensation fund investments. The carrying value of other financial instruments such as cash and cash equivalents, accounts and short-term notes receivable, accounts payable (including income taxes payable and accrued expenses) and borrowings under the Company’s line of credit approximate their fair values at December 31, 2024 and 2023, due to the short period of time to maturity or repayment.

Cash and Cash Equivalents and Restricted Cash Equivalents

Cash and cash equivalents and restricted cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk. The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits.

The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows.

December 31, 2024December 31, 2023December 31, 2022
(in thousands)
Cash and cash equivalents$56,776 $54,330 $26,279 
Restricted cash equivalents1
3,355 — — 
Total cash and cash equivalents and restricted cash equivalents$60,131 $54,330 $26,279 
1.On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of December 31, 2024. The trust account was set up in conjunction with a reduction in the Company’s letters of credit collateral obligation for insurance obligations.

Investments in Marketable Securities and Restricted Marketable Securities

Marketable securities are defined as fixed income investments which are highly liquid and can be readily purchased or sold through established markets. As of December 31, 2024 and 2023, the Company had marketable securities of $75.6 million and $93.1 million, respectively, comprised primarily of municipal bonds, U.S. treasury bonds, corporate bonds and other government bonds. These investments are accounted for as available-for-sale securities and are reported at fair value on the Company's Consolidated Balance Sheets. For the year ended December 31, 2024, $0.5 million of unrealized losses related to these investments were recorded in Other comprehensive (loss) income. For the years ended December 31, 2023 and 2022, $1.6 million of unrealized gains and $7.5 million of unrealized losses related to these marketable securities were recorded in Other comprehensive (loss) income, respectively. Unrealized gains and losses are recorded net of income taxes, with any income tax provision or benefit recorded once gains and losses are recognized.

These assets are held by the Company’s wholly-owned captive insurance company subsidiary as required by state insurance regulations. The Company’s investment policy is intended to manage the assets to achieve the goals of preserving principal, maintaining adequate liquidity at all times and maximizing returns subject to investment guidelines. The investment policy limits investment to certain types of instruments issued by institutions primarily with investment grade credit ratings and places restrictions on concentration by type and issuer.
The Company periodically reviews the investments in marketable securities and restricted marketable securities for credit impairment when an investment’s fair value declines below the amortized cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. As of December 31, 2024, management believes that the recorded value of the Company’s investments in marketable securities and restricted marketable securities was recoverable in all material respects.

Accounts and Notes Receivable

Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement and range from prepaid to 120 days. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided.

Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. Notes receivable are recorded at face value less any imputed interest assessed. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses.

Allowance for Doubtful Accounts

Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received.

Inventories and Supplies

Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (FIFO) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months.

Revenue Recognition

The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the expected value of consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration. Refer to Note 2 — Revenue herein for more regarding the Company’s revenue recognition policy.

Leases

The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direct of use of the asset, and the Company obtains substantially all of the economic benefits from the right of use.
Property and Equipment, Net

Property and equipment, with the exception of those pertaining to leases, are stated at cost, net of accumulated depreciation. Additions, renewals and improvements are capitalized, while maintenance and repair costs are expensed when incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in Investment and other income (loss), net on the Consolidated Statements of Comprehensive Income. Depreciation is recorded using the straight-line method over the following estimated useful lives: Housekeeping and Dietary equipment — 3 to 5 years; computer hardware and software — 5 years; and other, consisting of furniture and fixtures, leasehold improvements and vehicles — 5 to 10 years. Depreciation expense on property and equipment, inclusive of amortization of lease right-of-use assets, for the years ended December 31, 2024, 2023 and 2022 was $11.9 million, $10.5 million and $10.5 million, respectively.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not.

Uncertain income tax positions taken or expected to be taken in tax returns are reflected within the Company’s consolidated financial statements based on a recognition and measurement process.

The Company may from time to time be assessed interest or penalties by taxing jurisdictions, although any such assessments historically have been minimal and immaterial to its financial results. When the Company has received an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense. In addition, any interest or penalties relating to recognized uncertain tax positions would also be recorded in selling, general and administrative expense.

Earnings per Common Share

Basic earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock options and upon the vesting of restricted stock units (“RSUs”), deferred stock units (“DSUs”), and performance-based restricted stock units (“PSUs”).

Share-Based Compensation

The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes valuation model for stock options, using a Monte Carlo simulation for PSUs and using the share price on the date of grant for RSUs and DSUs. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive Income over the requisite service periods, with adjustments made for forfeitures as they occur.

Advertising Costs

Advertising costs are expensed when incurred. Advertising costs were not material for the years ended December 31, 2024, 2023 and 2022.

Impairment of Long-Lived Assets

The carrying amounts of long-lived assets are periodically reviewed to determine whether current events or circumstances warrant adjustment to such carrying amounts. Any impairment would be measured as the amount that the carrying value of such assets exceeds their fair value. Considerable management judgment is necessary to estimate the fair value of assets. Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell. No impairment loss was recognized on the Company’s long-lived assets during the years ended December 31, 2024, 2023 or 2022.
Goodwill and Other Intangible Assets

Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. Other intangible assets are amortized on a straight-line basis over their respective useful lives.

No impairment loss was recognized on the Company’s intangible assets or goodwill during the years ended December 31, 2024, 2023 or 2022.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid-in capital.

Authorized Shares of Common Stock

On June 18, 2024, the Company amended its Restated Articles of Incorporation to increase the number of authorized shares of common stock available for issuance from 100 million to 200 million, as approved by the requisite vote of the Company’s shareholders.

Investments in Equity Securities

The Company accounts for investments in equity securities using the equity method when the Company determines that it can exercise significant influence over the investee. The Company accounts for investments in equity securities at fair value when the Company determines that it cannot exercise significant influence over the investee. During the year ended December 31, 2024, the Company invested $2.8 million for a 25% ownership share in a health care technology company which specializes in the long-term and acute care markets which was accounted for as an equity method investment. Investments in equity securities are recorded within “Other long-term assets” in the Company’s Consolidated Balance Sheets. The Company’s proportionate share of earnings or losses of the investee are recorded within “Investment and other income, net” on the Company’s Consolidated Statements of Comprehensive Income. The Company elects to record its proportionate share of earnings or losses in equity method investments using a three-month lag based on the most recently available financial statements.

Concentrations of Credit Risk

The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, restricted cash equivalents, marketable securities, restricted marketable securities, deferred compensation funding and accounts and notes receivable. At December 31, 2024 and 2023, the majority of the Company’s cash and cash equivalents, restricted cash equivalents, marketable securities and restricted marketable securities were held in two large financial institution located in the United States. The Company’s marketable securities and restricted marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s deferred compensation funding consists of fund and money market investments all of which are highly liquid and held in a trust account.

The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until such new legislation or changes in existing regulations are fully implemented and governmental agencies issue applicable regulations or guidance.
Although the Company negotiates the pricing and other terms for the majority of our purchases of food and dining supplies directly with national manufacturers, the Company procures more than 50% of these products and other items through Sysco Corporation (“Sysco”). Sysco is responsible for tracking the Company’s orders and delivering products to the Company’s customer locations.
Significant Customer

For the years ended December 31, 2024, 2023 and 2022, Genesis Healthcare, Inc. (“Genesis”) accounted for $148.9 million or 8.7%, $181.4 million or 10.9% and $169.1 million or 10.0% of the Company’s consolidated revenues, respectively. As of December 31, 2024, the Company had outstanding accounts receivable and notes receivable of $46.1 million and $21.9 million, respectively, from Genesis. Although the Company expects to continue its relationship with Genesis, there can be no assurance thereof. Revenues generated from Genesis were included in both operating segments previously mentioned. Any extended discontinuance of revenues, or significant reduction, from this customer could, if not replaced, have a material impact on our operations. In addition, if Genesis fails to abide by current payment terms it could increase our accounts receivable balance and have a material adverse effect on our financial condition, results of operations, and cash flows. No other single customer or customer group represented more than 10% of consolidated revenues for the years ended December 31, 2024, 2023 and 2022.

Reclassification

Prior period line items in the Consolidated Balance Sheets and the Consolidated Statements of Stockholders’ Equity have been revised to conform with current period presentation.

Recent Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The Company adopted ASU 2023-07 for the annual period ended December 31, 2024. Refer to Note 12 — Segment Information herein for further information.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances effective tax rate reconciliation disclosure requirements and provides clarity to the disclosures of income taxes paid, income before taxes and provision for income taxes. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which amends the codification to enhance disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments are effective for fiscal years beginning after December 15, 2026. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company’s present or future consolidated financial statements.

Employee Retention Credit

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021.
The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021. Through February 14, 2025, the Company has been informed only that the IRS review of the ERC has been delayed, and no refunds or other material updates from the IRS regarding the ERC filing have been received. The Company believes that there is not reasonable assurance that any receipt of credits and compliance with the terms of the ERC will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” in the Consolidated Statements of Comprehensive Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations.
v3.25.0.1
Revenue
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue
Note 2 — Revenue

The Company presents its consolidated revenues disaggregated by reportable segment as Management evaluates the nature, amount, timing and uncertainty of the Company’s revenues by segment. Refer to Note 12 — Segment Information herein as well as the information below regarding the Company’s reportable segments.

Housekeeping

Housekeeping accounted for $765.4 million, $766.7 million and $795.7 million of the Company’s consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively. Housekeeping services consist of managing customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of the customers’ facilities, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at the customers’ facilities. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate housekeeping services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation.

Dietary

Dietary services accounted for $950.3 million, $904.7 million and $894.5 million of the Company’s consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively. Dietary services consist of managing customers’ dietary departments which are principally responsible for food purchasing, meal preparation and professional dietitian services, which include the development of menus that meet the dietary needs of residents. On-site management is responsible for all daily dietary department activities, with regular support provided by a District Manager specializing in dietary services. The Company also offers clinical consulting services to facilities which if contracted is a service bundled within the monthly service provided to customers. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate dietitian services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation.
Revenue Recognition

The Company’s revenues are derived from contracts with customers. The Company recognizes revenue to depict the transfer of promised goods and services to customers in amounts that reflect the consideration to which the Company is entitled in exchange for those goods and services. The Company’s costs of obtaining contracts are not material.

The Company performs services and provides goods in accordance with its contracts with its customers. Such contracts typically provide for a renewable service term, cancellable by either party upon 30 to 90 days’ notice, after an initial period of 60 to 120 days. A performance obligation is the unit of account under ASC 606 - Revenues from Contracts with Customers (“ASC 606”) and is defined as a promise in a contract to transfer a distinct good or service to the customer. The Company’s Housekeeping and Dietary contracts relate to the provision of bundles of goods, services or both, which represent a series of distinct goods and services that are substantially the same and that have the same pattern of transfer to the customer. The Company accounts for the series as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Revenue is recognized using the output method, which is based upon the delivery of goods and services to the customers’ facilities. In limited cases, the Company provides goods, services or both before the execution of a written contract. In these cases, the Company defers the recognition of revenue until a contract is executed. The amount of such deferred revenue was $0.2 million, less than $0.1 million and $0.3 million as of December 31, 2024, 2023 and 2022, respectively. Additionally, all such revenue amounts deferred as of December 31, 2023 were subsequently recognized as revenue during the year ended December 31, 2024.

The transaction price is the amount of consideration to which the Company is entitled in exchange for transferring promised goods or services to its customers. The transaction price does not include taxes assessed or collected. The Company’s contracts detail the fees that the Company charges for the goods and services it provides. For certain contracts which contain a variable component to the transaction price, the Company is required to make estimates of the amount of consideration to which the Company will be entitled, based on variability in resident and patient populations serviced, product usage, quantities consumed or history of implicit price concessions. The Company recognizes revenue related to such estimates when the Company determines that it is probable there will not be a significant reversal in the amount of revenue recognized. In instances where variable consideration exists and management’s estimate of variable consideration changes in subsequent periods, resulting in a change in transaction price, the Company records an adjustment to revenue on a cumulative catch-up basis. The Company’s contracts generally do not contain significant financing components, as payment terms are less than one year. In the event that the Company provides ongoing services to customers in active bankruptcy proceedings, in receivership or in other similar legal positions, the Company defers the recognition of revenue until cash is received, as the Company determines that collectability of substantially all of the entitled consideration in exchange for services provided is not probable for such customers until cash is received.

During the year ended December 31, 2023, the Company recorded a reduction to revenues of $13.8 million to reflect the Company’s change in estimate for price concessions based on new facts and circumstances related to a client’s out-of-court restructuring. Such adjustment reflects the Company’s current anticipated concession to be granted on certain amounts due as the Company’s current operating plans are to maintain providing services under this arrangement.

The Company allocates the transaction price to each performance obligation noting that the bundle of goods, services or goods and services provided under each Housekeeping and Dietary contract represents a single performance obligation that is satisfied over time. The Company recognizes the related revenue when it satisfies the performance obligation by transferring a bundle of promised goods, services or both to a customer. Such recognition is on a monthly or weekly basis, as goods are provided and services are performed. In some cases, the Company requires customers to pay in advance for goods and services to be provided. As of December 31, 2024, 2023 and 2022, the value of the contract liabilities associated with customer prepayments was $4.0 million, $3.2 million and $3.1 million, respectively. The Company recognized $1.9 million of revenue during the year ended December 31, 2024 which was recorded as a contract liability on December 31, 2023. The Company recognized $1.8 million of revenue during the year ended December 31, 2023 which was recorded as a contract liability on December 31, 2022.
Transaction Price Allocated to Remaining Performance Obligations

The Company recognizes revenue as it satisfies the performance obligations associated with contracts with customers, which due to the nature of the goods and services provided by the Company, are satisfied over time. Contracts may contain transaction prices that are fixed, variable or both. The Company’s contracts with customers typically provide for an initial term with renewable service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company has elected to apply the practical expedient that permits exclusion of information about the remaining performance obligations with original expected durations of one year or less. There were no remaining performance obligations with original expected durations of one year or longer as of December 31, 2024.
v3.25.0.1
Accounts and Notes Receivable
 12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Accounts and Notes Receivable
Note 3 — Accounts and Notes Receivable

The Company’s accounts and notes receivable balances consisted of the following as of December 31, 2024, 2023 and 2022:

December 31, 2024December 31, 2023December 31, 2022
(in thousands)
Short-term
Accounts receivable$418,427 $425,681 $375,225 
Allowance for doubtful accounts, accounts receivable(87,520)(80,817)(66,601)
Total net accounts receivable$330,907 $344,864 $308,624 
Notes receivable — short–term portion61,801 45,078 31,744 
Allowance for doubtful accounts, notes receivable — short–term portion(10,372)(6,433)(3,591)
Total net notes receivable — short–term portion$51,429 $38,645 $28,153 
Long-term
Notes receivable$43,944 $29,281 $35,882 
Allowance for doubtful accounts(2,890)(4,449)(3,273)
Total net long-term notes receivable$41,054 $24,832 $32,609 
Total net accounts and notes receivable$423,390 $408,341 $369,386 

The Company makes credit decisions on a case-by-case basis after reviewing a number of qualitative and quantitative factors related to the specific customer as well as current industry variables that may impact that customer. There are a variety of factors that impact a customer’s ability to pay in accordance with the Company’s contracts. These factors include, but are not limited to, fluctuating census numbers, litigation costs and the customer’s participation in programs funded by federal and state governmental agencies. Deviations in the timing or amounts of reimbursements under those programs can impact the customer’s cash flows and its ability to make timely payments. However, the customer’s obligation to pay the Company in accordance with the contract is not contingent upon the customer’s cash flow. Notwithstanding the Company’s efforts to minimize its credit risk exposure, the aforementioned factors, as well as other factors that impact customer cash flows or ability to make timely payments, could have an indirect, yet material, adverse effect on the Company’s results of operations and financial condition.

Fluctuations in net accounts and notes receivable are generally attributable to a variety of factors including, but not limited to, the timing of cash receipts from customers and the inception, transition, modification or termination of customer relationships. The Company deploys significant resources and invests in tools and processes to optimize Management’s credit and collections efforts. When appropriate, the Company utilizes interest-bearing promissory notes to enhance the collectability of amounts due, by instituting definitive repayment plans and providing a means by which to further evidence the amounts owed. In addition, the Company may amend contracts from full service to management-only arrangements, or adjust contractual payment terms, to accommodate customers who have in good faith established clearly-defined plans for addressing cash flow issues. These efforts are intended to minimize the Company’s collections risk.

At December 31, 2024, the face value and discounted value of notes receivable with imputed interest were $39.7 million and $35.9 million, respectively. At December 31, 2023, the face value and discounted value of notes receivable with imputed interest were $7.6 million and $6.6 million, respectively. The effective interest rates applied on notes with imputed interest at December 31, 2024 and 2023 were 6.9% and 8.0%, respectively.
v3.25.0.1
Allowance for Doubtful Accounts
 12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Allowance for Doubtful Accounts
Note 4 — Allowance for Doubtful Accounts

In making the Company’s credit evaluations, management considers the general collection risk associated with trends in the long-term care industry. The Company establishes credit limits through payment terms with customers, performs ongoing credit evaluations and monitors accounts on an aging schedule basis to minimize the risk of loss. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future industry trends change in such a manner as to negatively impact their cash flows. As a result, the Company’s future collection experience could differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.

The Company evaluates its accounts and notes receivable for expected credit losses quarterly. Accounts receivable are evaluated based on internally developed credit quality indicators derived from the aging of receivables. Notes receivable are evaluated based on internally developed credit quality indicators derived from management’s assessment of collection risk. At the end of each period, the Company sets a reserve for expected credit losses on standard accounts and notes receivable based on the Company’s historical loss rates. Accounts and notes receivable with an elevated risk profile, which are from customers who have filed bankruptcy or are subject to collections activity, are aggregated and evaluated to determine the total reserve for the class of receivable. Additionally, starting in the year ended December 31, 2024, for notes receivable management evaluates standard receivables based on whether the customer is current (paying within 60 days of terms) or delinquent (paying outside of 60 days of terms). As of December 31, 2024, the Genesis note receivable was classified as delinquent.

ASC 326-20 - Financial Instruments - Credit Losses (“ASC 326-20”) permits entities to make an accounting policy election not to measure an estimate for credit losses on accrued interest if those entities write off accrued interest deemed uncollectible in a timely manner. The Company follows an income recognition policy on all interest earned on notes receivable. Under such policy the Company accounts for all notes receivable on a non-accrual basis and defers the recognition of any interest income until receipt of cash payments. This policy was established based on the Company’s history of collections of interest on outstanding notes receivable, as we do not deem it probable that we will receive substantially all interest on outstanding notes receivable. Accordingly, the Company does not record a credit loss adjustment for accrued interest. For the years ended December 31, 2024, 2023 and 2022, the Company recognized $2.8 million, $2.8 million and $1.1 million in interest income from notes receivable, respectively.

In 2024, LaVie Care Centers, LLC and certain affiliated entities (“LaVie”), several of which are customers of the Company, filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Northern District of Georgia. The Company increased the allowance for doubtful accounts by $17.6 million related to outstanding LaVie invoices during the year ended December 31, 2024. The Company continues to provide services to LaVie post-petition.

The following tables present the Company’s three tiers of notes receivable for the years ended December 31, 2024 and 2023, respectively, further disaggregated by year of origination, as well as write-off activity:

Notes Receivable as of December 31, 2024
Amortized Cost Basis by Origination Year
20242023202220212020PriorTotal
(in thousands)
Notes Receivable
Standard notes receivable$53,592 $7,282 $15,743 $— $— $— $76,617 
Delinquent notes receivable$499 $1,055 $1,942 $671 $— $21,933 $26,100 
Elevated risk notes receivable$— $1,537 $— $— $1,491 $— $3,028 
Current-period gross write-offs$— $742 $483 $3,024 $— $26 $4,275 
Current-period recoveries— — — — — — — 
Current-period net write-offs $— $742 $483 $3,024 $— $26 $4,275 
Notes Receivable as of December 31, 2023
Amortized Cost Basis by Origination Year
20232022202120202019PriorTotal
(in thousands)
Notes Receivable
Standard notes receivable1
$18,175 $25,505 $855 $1,529 $3 $21,033 $67,100 
Elevated risk notes receivable$— $— $7,259 $— $— $— $7,259 
Current-period gross write-offs$— $189 $— $— $50 $2,253 $2,492 
Current-period recoveries— — — — — — — 
Current-period net write-offs$— $189 $— $— $50 $2,253 $2,492 
1.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.

The following tables provide information as to the status of payment on the Company’s gross notes receivable which were past due as of December 31, 2024 and 2023, respectively:

 Age Analysis of Past-Due Notes Receivable as of December 31, 2024
0-90 Days91 - 180 DaysGreater than 181 DaysTotal
(in thousands)
Notes Receivable
Standard notes receivable$142 $— $— $142 
Delinquent notes receivable1
761 682 23,151 24,594 
Elevated risk notes receivable225 225 2,429 2,879 
$1,128 $907 $25,580 $27,615 
1.Included within the Delinquent notes receivable past-due balance is the entire balance of notes receivable due from Genesis.

Age Analysis of Past-Due Notes Receivable as of December 31, 2023
0-90 Days91 - 180 DaysGreater than 181 DaysTotal
(in thousands)
Notes Receivable
Standard notes receivable1
$3,851 $4,852 $6,914 $15,617 
Elevated risk notes receivable569 569 949 2,087 
$4,420 $5,421 $7,863 $17,704 
1.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2024 and 2023, respectively:
Allowance for doubtful accounts
Portfolio Segment:December 31,
2023
Reclassifications1
Write-Offs2
Bad Debt ExpenseDecember 31,
2024
(in thousands)
Accounts receivable$80,819 $— $(33,402)$40,103 $87,520 
Notes receivable
Standard notes receivable$6,125 $(2,615)$— $1,586 $5,096 
Delinquent notes receivable1
— 2,615 (1,252)4,663 6,026 
Elevated risk notes receivable4,755 — (3,023)408 2,140 
Total notes receivable$10,880 $— $(4,275)$6,657 $13,262 
Total accounts and notes receivable$91,699 $— $(37,677)$46,760 $100,782 
1.Delinquent notes receivable were identified as a new loss pool during the year ended December 31, 2024.
2.Write-offs are shown net of recoveries. During the year ended December 31, 2024, the Company collected $0.1 million of accounts receivables that were recovered subsequent to being written-off.
Allowance for doubtful accounts
Portfolio Segment:December 31,
2022
Write-Offs1
Bad Debt ExpenseDecember 31,
2023
(in thousands)
Accounts receivable$66,601 $(14,877)$29,095 $80,819 
Notes receivable
Standard notes receivable2
$6,052 $(1,646)$1,719 $6,125 
Elevated risk notes receivable811 (846)4,790 4,755 
Total notes receivable$6,863 $(2,492)$6,509 $10,880 
Total accounts and notes receivable$73,464 $(17,369)$35,604 $91,699 
1.Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off.
2.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
v3.25.0.1
Changes in Accumulated Other Comprehensive Loss by Component
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Changes in Accumulated Other Comprehensive Loss by Component
Note 5 — Changes in Accumulated Other Comprehensive Loss by Component

For the years ended December 31, 2024, 2023 and 2022, the Company’s accumulated other comprehensive loss consisted of unrealized gains and losses from the Company’s available-for-sale marketable securities and restricted marketable securities. The following tables provide a summary of the changes in accumulated other comprehensive loss, net of taxes:
Unrealized Gains and (Losses) on Available-for-Sale Securities1
Year Ended December 31,
202420232022
(in thousands)
Accumulated other comprehensive (loss) income — beginning balance$(1,844)$(3,477)$4,000 
Other comprehensive (loss) income before reclassifications(753)1,624 (7,505)
Losses reclassified from other comprehensive (loss) income²280 9 28 
Net current period other comprehensive (loss) income³(473)1,633 (7,477)
Accumulated other comprehensive loss — ending balance$(2,317)$(1,844)$(3,477)
1.All amounts are net of tax.
2.Realized gains and losses were recorded pre-tax under “Investment and other income (loss), net” in the Consolidated Statements of Comprehensive Income. For the year ended December 31, 2024, the Company recorded $0.4 million of realized losses from the sale of available-for-sale securities. For the years ended December 31, 2023 and 2022, the Company recorded less than $0.1 million of realized losses from the sale of available-for-sale securities. Refer to Note 9 — Fair Value Measurements herein for further information.
3.For the year ended December 31, 2024, the change in accumulated other comprehensive loss was net of a tax benefit of $0.1 million. For the years ended December 31, 2023 and 2022, the changes in accumulated other comprehensive loss were net of a tax expense of $0.4 million and benefit of $2.0 million, respectively.

Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income
Year Ended December 31,
202420232022
(in thousands)
Losses from the sale of available-for-sale securities$(355)$(12)$(37)
Tax benefit75 3 9 
Net loss reclassified from accumulated other comprehensive income$(280)$(9)$(28)
v3.25.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment
Note 6 — Property and Equipment

Property and equipment are recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.

The following table sets forth the amounts of property and equipment by each class of depreciable asset as of December 31, 2024 and December 31, 2023:
December 31, 2024December 31, 2023
(in thousands)
Housekeeping and Dietary equipment$17,052 $15,764 
Computer hardware and software8,196 6,870 
Operating lease — right-of-use assets29,669 27,099 
Other1
904 1,070 
Total property and equipment, at cost55,821 50,803 
Less accumulated depreciation2
27,623 22,029 
Total property and equipment, net$28,198 $28,774 
1.Includes furniture and fixtures, leasehold improvements and autos and trucks.
2.Includes $13.2 million and $9.4 million related to accumulated depreciation on Operating lease – right-of-use assets as of December 31, 2024 and 2023, respectively.

Depreciation expense for the years ended December 31, 2024, 2023 and 2022 was $11.9 million, $10.5 million, and $10.5 million, respectively. Of the depreciation expense recorded for the years ended December 31, 2024, 2023 and 2022, $7.8 million, $6.4 million and $6.1 million related to the depreciation of the Company’s operating lease - right-of-use assets (“ROU Assets”), respectively.

At December 31, 2024, 2023 and 2022, accrued purchases of property and equipment were $0.5 million, $0.7 million, and $0.3 million, respectively.
v3.25.0.1
Leases
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Leases
Note 7 — Leases

The Company recognizes ROU Assets and lease liabilities for automobiles, office buildings, IT equipment and small storage units for the temporary storage of operational equipment. The Company’s leases have remaining lease terms ranging from less than 1 year to 5 years. The Company recognizes extension options as part of the initial lease term for ROU Assets and lease liabilities when it is reasonably certain that the Company will exercise the extension option upon the completion of the initial lease term. Most leases include the option to terminate the lease within 1 year.

The Company uses practical expedients offered under the ASC 842 - Leases (“ASC 842”) to combine lease and non-lease components within leasing arrangements and to recognize the payments associated with short-term leases in earnings on a straight-line basis over the lease term, with the cost associated with variable lease payments recognized when incurred. These accounting policy elections impact the value of the Company’s ROU Assets and lease liabilities. The value of the Company’s ROU Assets is determined as the carrying value of its leasing arrangements and is recorded in Property and equipment, net on the Company’s Consolidated Balance Sheets. The value of the Company’s lease liabilities is the present value of fixed lease payments not yet paid, which is discounted using either the rate implicit in the lease contract if that rate can be determined or the Company’s incremental borrowing rate (“IBR”) and is recorded in Other accrued expenses and current liabilities and Lease liability — long-term on the Company’s Consolidated Balance Sheets. The Company’s IBR is determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment.

Any future lease payments that are not fixed based on the terms of the lease contract, or fluctuate based on a factor other than an index or rate, are considered variable lease payments and are not included in the value of the Company’s ROU Assets or lease liabilities. The Company’s variable lease payments are mostly incurred from automobile leases and relate to miscellaneous transportation costs including repair costs, insurance, and terminal rental adjustment payments due at lease settlement. Such rental adjustment payments can result in a reduction to the Company’s total variable lease payments.
As of December 31, 2024 and 2023, the Company’s short-term portion of lease obligations were $8.4 million and $7.4 million, respectively, and are recorded in Other accrued expenses and current liabilities with the remaining balance recognized under the Lease liability — long-term portion caption on the Company’s Consolidated Balance Sheets. The corresponding expense for the Company’s lease commitments are primarily recorded in selling, general and administrative expense on the Company’s Consolidated Statements of Comprehensive Income.

Components of lease expense are presented below for the years ended December 31, 2024, 2023 and 2022.

Year Ended December 31,
202420232022
(in thousands)
Lease cost
Operating lease cost$7,799 $6,400 $5,673 
Short-term lease cost883 1,037 1,265 
Variable lease cost1,609 1,952 857 
Total lease cost$10,291 $9,389 $7,795 

Supplemental information is presented below for the years ended December 31, 2024, 2023 and 2022.

Year Ended December 31,
202420232022
(dollar amounts in thousands)
Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$8,125$6,808$6,385
ROU Assets obtained in exchange for lease obligations3,7216,0641,650
Weighted-average remaining lease term — operating leases2.6 years3.3 years4.2 years
Weighted-average discount rate — operating leases6.3 %6.6 %4.4 %

During the years ended December 31, 2024 and 2023, the Company’s ROU Assets and lease liabilities were reduced by $0.8 million and $2.7 million, respectively due to lease cancellations.

The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of December 31, 2024:

Period/YearOperating Leases
(in thousands)
2025$8,420 
20265,746 
20272,264 
20281,389 
2029116 
Thereafter— 
Total minimum lease payments$17,935 
Less: imputed lease payments1,480 
Present value of lease liabilities$16,455 
v3.25.0.1
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
Note 8 — Goodwill and Other Intangible Assets

Goodwill

Goodwill represents the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is not amortized but is evaluated for impairment on an annual basis or more frequently if impairment indicators arise. To date, the Company has not recognized an impairment of its goodwill.

The following table sets forth the amounts of goodwill by reportable segment as of December 31, 2024 and 2023:
December 31, 2024December 31, 2023
(in thousands)
Housekeeping$42,377 $42,377 
Dietary33,152 33,152 
Total Goodwill$75,529 $75,529 

Intangible Assets

The Company’s other intangible assets consist of customer relationships, trade names, patents and non-compete agreements which were obtained through acquisitions and are recorded at their fair values at the date of acquisition. The following table sets forth the amounts of other intangible assets as of December 31, 2024 and 2023:
December 31, 2024December 31, 2023
Gross AmountAccumulated AmortizationNet AmountGross AmountAccumulated AmortizationNet Amount
(in thousands)
Customer relationships$45,634 $38,093 $7,541 $45,634 $35,718 $9,916 
Trade names1,731 466 1,265 1,731 329 1,402 
Patents1,086 505 581 1,086 369 717 
Non-compete agreements233 178 55 233 141 92 
Total other intangible assets$48,684 $39,242 $9,442 $48,684 $36,557 $12,127 

No acquisitions occurred during the year ended December 31, 2024. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives. The weighted-average amortization period of customer relationships, trade names, patents, and non-compete agreements are approximately 10 years, 13 years, 8 years, and 4 years, respectively.

The following table sets forth the estimated amortization expense for intangibles subject to amortization for 2025, the following four fiscal years and thereafter:
Period/YearTotal Amortization Expense
(in thousands)
2025$2,685 
2026$2,666 
2027$1,195 
2028$613 
2029$509 
Thereafter$1,774 
Total$9,442 

Amortization expense for the years ended December 31, 2024, 2023 and 2022 was $2.7 million, $3.8 million and $4.9 million, respectively.
v3.25.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 9 — Fair Value Measurements

The Company’s current assets and current liabilities are financial instruments and most of these items (other than marketable securities, restricted marketable securities, inventories and supplies and the short-term portion of deferred compensation assets and liabilities) are recorded at cost in the Consolidated Balance Sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. The carrying value of the Company’s line of credit represents the outstanding amount of the borrowings, which approximates fair value. The Company’s financial assets that are measured at fair value on a recurring basis are its marketable securities, restricted marketable securities and deferred compensation funding. The recorded values of all of the financial instruments approximate their current fair values because of their nature, stated interest rates and respective maturity dates or durations.

The Company’s marketable securities and restricted marketable securities are held by the Company’s captive insurance company to satisfy capital requirements of the state regulator related to captive insurance companies. Restricted marketable securities are held by the Company’s captive insurance company as collateral for certain insurance coverages. Such securities are primarily comprised of municipal bonds, treasury notes, corporate bonds and other government bonds which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses associated with these investments are included in Unrealized (loss) gain on available-for-sale marketable securities, net of taxes within the Consolidated Statements of Comprehensive Income. Marketable securities and restricted marketable securities are classified within Level 2 of the fair value hierarchy, as these securities are measured using quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable. Such valuations are determined by a third-party pricing service. For the year ended December 31, 2024, the Company recorded unrealized losses, net of taxes of $0.5 million on marketable securities. For the years ended December 31, 2023 and 2022, the Company recorded unrealized gains, net of taxes of $1.6 million and unrealized losses, net of taxes of $7.5 million on marketable securities, respectively.

For the years ended December 31, 2024, 2023 and 2022, the Company received total proceeds, less the amount of interest received, of $67.0 million, $2.0 million and $10.4 million, respectively, from sales of available-for-sale securities. These sales resulted in realized losses of $0.4 million for the year ended December 31, 2024 and realized losses of less than $0.1 million for the years ended December 31, 2023 and 2022. Such gains and losses were recorded in Investment and other income (loss), net in the Consolidated Statements of Comprehensive Income. The basis for the sale of these securities was the specific identification of each security sold during the period.

As part of a prior period acquisition of a prepackaged meal manufacturer, the Company agreed to pay royalties to the seller on all future product sales. The Company records a liability for the expected future payments within Other long-term liabilities on the Consolidated Balance Sheets. The fair value of this liability is measured using forecasted sales models (Level 3). For the years ended December 31, 2024, 2023 and 2022, the Company recorded realized gains of $0.6 million, $1.1 million and $2.4 million, respectively, within Costs of services provided in the Consolidated Statements of Comprehensive Income related to the measurement of the liability at each balance sheet date.

The investments under the deferred compensation plan are accounted for as trading securities and unrealized gains or losses are recorded within Investment and other income (loss), net in the Consolidated Statements of Comprehensive Income. The fair values of these investments are determined based on quoted market prices (Level 1) or the net asset value (“NAV”) of underlying share investments (Level 2). For the years ended December 31, 2024, 2023 and 2022, the Company recorded unrealized gains of $8.3 million, unrealized gains of $6.6 million and unrealized losses of $9.3 million, respectively, related to trading securities still held at the respective reporting dates.
The following table summarizes the contractual maturities of debt securities held as of December 31, 2024 and 2023 which are classified within “Marketable securities, at fair value” and “Restricted marketable securities, at fair value” in the Consolidated Balance Sheets:
Debt Securities — Available-for-Sale
Contractual maturity:December 31, 2024December 31, 2023
(in thousands)
Marketable securities, at fair value
Maturing in one year or less$653 $6,324 
Maturing in second year through fifth year23,341 34,939 
Maturing in sixth year through tenth year13,113 39,309 
Maturing after ten years13,428 12,559 
Total marketable securities, at fair value$50,535 $93,131 
Restricted marketable securities, at fair value
Maturing in one year or less$2,474 $— 
Maturing in second year through fifth year15,774 — 
Maturing in sixth year through tenth year5,837 — 
Maturing after ten years1,020 — 
Total restricted marketable securities, at fair value$25,105 $— 
Total debt securities — available-for-sale$75,640 $93,131 
The following tables provide fair value measurement information for the Company’s financial assets, including marketable securities, restricted marketable securities and deferred compensation fund investments as of December 31, 2024 and 2023:

As of December 31, 2024
Fair Value Measurement Using:
(amounts in thousands)Carrying AmountTotal Fair ValueQuoted Prices in Active Markets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Marketable securities
Municipal bonds — taxable$9,600 $9,600 $— $9,600 $— 
Municipal bonds — non-taxable40,935 40,935 — 40,935 — 
Total marketable securities$50,535 $50,535 $— $50,535 $— 
Restricted marketable securities
U.S. treasury bonds$7,309 $7,309 $— $7,309 $— 
U.S. government agency bonds1,218 1,218 — 1,218 — 
International fixed income bonds652 652 — 652 — 
Corporate bonds6,796 6,796 — 6,796 — 
Municipal bonds — taxable9,130 9,130 — 9,130 — 
Total restricted marketable securities$25,105 $25,105 $— $25,105 $— 
Deferred compensation plan
Money market1
$1,961 $1,961 $— $1,961 $— 
Commodities295 295 295 — — 
Fixed income4,417 4,417 4,417 — — 
International4,999 4,999 4,999 — — 
Large cap blend6,669 6,669 6,669 — — 
Large cap growth18,524 18,524 18,524 — — 
Large cap value6,964 6,964 6,964 — — 
Mid cap blend3,957 3,957 3,957 — — 
Real estate372 372 372 — — 
Small cap blend2,980 2,980 2,980 — — 
Deferred compensation plan2
$51,138 $51,138 $49,177 $1,961 $— 
As of December 31, 2023
Fair Value Measurement Using:
(amounts in thousands)Carrying
Amount		Total Fair
Value		Quoted Prices in Active Markets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Marketable securities
Municipal bonds — non-taxable$93,131 $93,131 $— $93,131 $— 
Deferred compensation plan
Money market1
$2,007 $2,007 $— $2,007 $— 
Commodities298 298 298 — — 
Fixed income4,254 4,254 4,254 — — 
International4,621 4,621 4,621 — — 
Large cap blend5,053 5,053 5,053 — — 
Large cap growth13,886 13,886 13,886 — — 
Large cap value5,964 5,964 5,964 — — 
Mid cap blend3,192 3,192 3,192 — — 
Real estate374 374 374 — — 
Small cap blend2,664 2,664 2,664 — — 
Deferred compensation plan2
$42,313 $42,313 $40,306 $2,007 $— 
1.The fair value of the money market is based on the NAV of the shares held by the plan at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment.
2.The deferred compensation plan carrying amounts and total fair value amounts as of December 31, 2024 and 2023 are inclusive of $1.5 million each of holdings expected to be paid to former employees within the next twelve months which were recorded under Prepaid expenses and other assets in the Company’s Consolidated Balance Sheets.
The following table shows the amortized cost, unrealized gains and losses, and estimated fair value of the Company’s debt securities as of December 31, 2024 and 2023:
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Credit Impairment Losses1
December 31, 2024(in thousands)
Type of security:
Marketable securities
Municipal bonds — taxable$10,276 $— $(676)$9,600 $— 
Municipal bonds — non-taxable43,255 — (2,320)40,935 — 
Total marketable securities$53,531 $— $(2,996)$50,535 $— 
Restricted marketable securities
U.S. treasury bonds$7,276 $38 $(5)$7,309 
U.S. government agency bonds1,208 10 — 1,218 
International fixed income bonds647 5 — 652 
Corporate bonds6,780 30 (14)6,796 
Municipal bonds — taxable9,131 40 (41)9,130 
Total restricted marketable securities$25,042 $123 $(60)$25,105 $— 
Total debt securities — available-for-sale$78,573 $123 $(3,056)$75,640 $— 
December 31, 2023
Type of security:
Municipal bonds — non-taxable$95,466 $387 $(2,722)$93,131 $— 
Total debt securities — available-for-sale$95,466 $387 $(2,722)$93,131 $— 
v3.25.0.1
Share-Based Compensation
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
Note 10 — Share-Based Compensation

The components of the Company’s share-based compensation expense for the years ended December 31, 2024, 2023 and 2022 are as follows:
Year Ended December 31,
202420232022
(in thousands)
Stock options$708 $969 $1,253 
Restricted stock units and deferred stock units6,870 6,657 6,972 
Performance stock units1,341 1,210 819 
Employee Stock Purchase Plan246 149 170 
Total pre-tax share-based compensation expense charged against income$9,165 $8,985 $9,214 
Total recognized tax deficiency related to share-based compensation$(607)$(773)$(783)

At December 31, 2024 and 2023, the unrecognized compensation cost related to unvested stock options and awards was $16.2 million and $16.5 million, respectively. The weighted average period over which these awards will vest was approximately 2.8 years as of both December 31, 2024 and December 31, 2023.

The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023 and 2022:

Year Ended December 31,
202420232022
(in thousands)
Selling, general and administrative expense$9,086 $8,942 $9,160 
Costs of services provided79 43 54 
Total share-based compensation expense$9,165 $8,985 $9,214 

Amended 2020 Omnibus Incentive Plan

On May 26, 2020, the Company adopted the 2020 Omnibus Incentive Plan (the “2020 Plan”) after approval by the Company’s shareholders at the 2020 Annual Meeting of Shareholders. On May 30, 2023, the Company increased the authorized shares under the 2020 Omnibus Incentive Plan (as amended, the “Amended 2020 Plan”) by 2.5 million shares after approval by the Company’s shareholders at the 2023 Annual Meeting of Shareholders. The Amended 2020 Plan provides that current or prospective officers, employees, non-employee directors and advisors can receive share-based awards such as stock options, performance stock units, restricted stock units and other stock awards. The Amended 2020 Plan seeks to encourage profitability and growth of the Company through short-term and long-term incentives that are consistent with the Company’s operating objectives.

As of December 31, 2024, there were 6.7 million shares of common stock reserved for issuance under the Amended 2020 Plan, of which 2.4 million are available for future grant. The amount of shares available for issuance under the Amended 2020 Plan will increase when outstanding awards under the Company’s Second Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) are subsequently forfeited, terminated, lapsed or satisfied thereunder in cash or property other than shares. No stock award will have a term in excess of 10 years. The Nominating, Compensation and Stock Option Committee (the “NCSO”) of the Board of Directors is responsible for determining the terms of the grants in accordance with the Amended 2020 Plan.
Stock Options

A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023 and changes during the year ended December 31, 2024 are as follows:
Stock Options Outstanding
Number of SharesWeighted Average Exercise Price
(in thousands)
December 31, 20232,438 $30.43 
Granted290 $10.36 
Exercised— $— 
Forfeited(1)$24.43 
Expired(199)$29.12 
December 31, 20242,528 $28.23 

The weighted average grant-date fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022 was $5.06, $6.53 and $4.06 per common share, respectively. No stock options were exercised during the years ended December 31, 2024 and 2023. The total intrinsic value of stock options exercised during the year ended December 31, 2022 was $0.1 million. The total fair value of stock options vested during the years ended December 31, 2024, 2023 and 2022 were $1.0 million, $1.3 million and $1.8 million, respectively.

For the year ended December 31, 2024 there was no tax deficiency realized from stock options exercised. For the years ended December 31, 2023 and 2022 the tax deficiency realized from stock options exercised was immaterial.

The fair value of stock option awards granted in 2024, 2023 and 2022 were estimated on the dates of grant using the Black-Scholes option valuation model with the following assumptions:
Year Ended December 31,
202420232022
Risk-free interest rate3.9 %4.0 %1.5 %
Weighted average expected life7.0 years6.9 years6.7 years
Expected volatility40.5 %39.5 %36.6 %
Dividend yield— %— %4.6 %

The following table summarizes other information about the stock options at December 31, 2024:
December 31, 2024
(amounts in thousands, except per share data)
Outstanding:
Aggregate intrinsic value$0.4 
Weighted average remaining contractual life4.5 years
Exercisable:
Number of options1,737 
Weighted average exercise price$33.91 
Aggregate intrinsic value$— 
Weighted average remaining contractual life3.0 years

Restricted Stock Units and Deferred Stock Units

The fair value of outstanding restricted stock units (“RSUs”) and deferred stock units (“DSUs”) was determined based on the market price of the shares on the date of grant. During the years ended December 31, 2024, 2023 and 2022, the Company granted 0.8 million, 0.5 million and 0.4 million RSUs and DSUs with weighted average grant date fair values of $10.39, $13.72 and $18.06 per unit, respectively.
A summary of the outstanding RSUs and DSUs as of December 31, 2023 and changes during the year ended December 31, 2024 is as follows:
Restricted Stock Units & Deferred Stock Units
NumberWeighted Average Grant Date Fair Value
(in thousands)
December 31, 20231,102 $18.57 
Granted775 $10.39 
Vested(298)$21.68 
Forfeited(63)$13.56 
December 31, 20241,516 $13.98 

The weighted average remaining vesting period for the unvested RSUs is 3.1 years.

The weighted average grant-date fair values and total fair values of RSUs vested during 2024, 2023 and 2022 were as follows:
Year Ended December 31,
202420232022
(in thousands, except per share data)
Weighted average grant-date fair value of restricted stock units granted$10.39 $13.72 $18.06 
Total fair value of restricted stock units and restricted shares vested$3,257 $2,991 $3,307 

The Company grants DSUs to non-employee directors. Once vested, the recipient shall be entitled to receive a lump sum payment of a number of shares equal to the total number of DSUs issued to such recipient upon the first to occur of (i) the five year anniversary of the date of grant, (ii) the recipient’s death, disability or separation of service from the Board, or (iii) a change of control (as defined by the Amended 2020 Plan). Non-employee directors can also elect to receive their Board of Directors retainer in the form of DSUs in lieu of cash. DSUs issued in lieu of cash for retainers vest immediately. The number of DSUs granted to these directors is determined based on the stock price on the award date and approximates the cash value the directors would otherwise receive for their retainer. Three non-employee directors made an election in 2023 to receive DSUs in lieu of cash for their 2024 Board of Directors retainer.

On May 28, 2024, the NCSO granted an aggregate of 30,000 DSUs to the Company’s non-employee directors. Each DSU award granted vests in one year. The unrecognized share-based compensation cost of DSU awards at December 31, 2024 is $0.1 million and is expected to be recognized over a weighted-average period of 0.4 years.

Performance Stock Units

On January 3, 2024, the NCSO granted 0.1 million Performance Stock Units (“PSUs”) to the Company’s executive officers. Such PSUs are contingent upon the achievement of certain total shareholder return (“TSR”) targets as compared to the TSR of the S&P 400 MidCap Index and the participant’s continued employment with the Company for the three year period ending December 31, 2026, the date at which such awards vest. The unrecognized share-based compensation cost of the TSR-based PSU awards at December 31, 2024 is $1.4 million and is expected to be recognized over a weighted-average period of 1.4 years.
A summary of the outstanding PSUs as of December 31, 2023 and changes during the year ended December 31, 2024 is as follows:
Performance Stock Units
NumberWeighted Average Grant Date Fair Value
(in thousands)
December 31, 2023175 $21.52 
Granted118 $11.85 
Vested— $— 
Forfeited(35)$34.52 
December 31, 2024258 $15.31 

Employee Stock Purchase Plan

The Company’s Employee Stock Purchase Plan (“ESPP”) is currently available through 2026 to all eligible employees. All full-time and part-time employees who work an average of 20 hours per week and have completed two years of continuous service with the Company are eligible to participate. Annual offerings commence and terminate on the respective year’s first and last calendar day.

Under the ESPP, the Company is authorized to issue up to 4.1 million shares of its common stock to its employees. Pursuant to such authorization, there are 1.7 million shares available for future grant at December 31, 2024. Under the terms of the ESPP, participants may contribute through payroll deductions up to $21,250 (85% of IRS limitation) of their compensation toward the purchase of the Company’s common stock. No employee may purchase common stock which exceeds $25,000 in fair market value (determined on the option date) for each calendar year. The per option price is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the last day of the offering period.

The following table summarizes information about the Company’s ESPP annual offerings for the years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
202420232022
(in thousands, except per share data)
Common shares purchased88 95 95 
Per common share purchase price$8.81 $8.81 $10.20 

The expense associated with the options granted under the ESPP during the year ended December 31, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions:
Year Ended December 31,
20242023
Risk-free interest rate4.8%4.8%
Weighted average expected life (years)1.01.0
Expected volatility37.1%42.9%
Dividend yield—%7.1%

Deferred Compensation Plan

The Company offers a Supplemental Executive Retirement Plan (“SERP”) for executives and certain key employees. The SERP is not qualified under Section 401 of the Internal Revenue Code. The SERP allows participants to defer up to 25% of their earned income on a pre-tax basis, and as of the last day of each plan year, each participant will be credited with a 25% match of up to 15% of their earnings deferred in the form of the Company’s common stock based on the then-current market value. SERP participants fully vest in the Company’s matching contribution three years from the first day of the initial year of participation. The income deferred and the matching contributions are unsecured and subject to the claims of the Company’s general creditors.
Under the SERP, the Company is authorized to issue 1.0 million shares of its common stock to its employees. Pursuant to such authorization, the Company has 0.2 million shares available for future grant at December 31, 2024. At the time of issuance, such shares are accounted for at cost as treasury stock. At December 31, 2024, approximately 0.4 million of shares granted under the SERP are vested and remain in the respective active participants’ accounts with the trustee.

The following table summarizes information about the SERP during the plan years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
 202420232022
(in thousands)
SERP expense 1
$579 $533 $486 
Treasury shares issued to fund SERP expense2
49 50 40 
Year end SERP trust account balance3
$51,138 $42,313 $35,111 
Unrealized gain (loss) recorded in SERP liability account$8,241 $6,684 $(9,178)
1.Both the SERP match and the deferrals are included in the selling, general and administrative caption in the Consolidated Statements of Comprehensive Income.
2.Shares related to the SERP match for each year are funded at the beginning of the subsequent year.
3.SERP trust account investments are recorded at their fair value which is based on quoted market prices. Differences between such amounts in the table above and the deferred compensation funding asset reported on the Company’s Consolidated Balance Sheets represent the value of Company common stock held in the Plan participants’ trust accounts and reported by the Company as treasury stock in the Company’s Consolidated Balance Sheets.
v3.25.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
Note 11 — Income Taxes

The following table summarizes the provision for income taxes:
Year Ended December 31,
202420232022
(amounts in thousands)
Current:
Federal$12,275 $13,728 $3,022 
State4,139 5,762 2,381 
$16,414 $19,490 $5,403 
Deferred:
Federal$(2,304)$(4,183)$4,163 
State(640)(637)744 
$(2,944)$(4,820)$4,907 
Tax provision$13,470 $14,670 $10,310 

Deferred income taxes are recorded using the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and income tax basis of assets and liabilities.
Significant components of the Company’s federal and state deferred tax asset and liability balances were as follows:
 Year Ended December 31,
 20242023
(in thousands)
Deferred tax assets:
Allowance for doubtful accounts$25,138 $22,788 
Deferred compensation9,159 9,048 
Accrued insurance claims5,277 5,580 
Non-deductible reserves497 169 
Lease liabilities4,214 4,765 
Share based compensation3,312 2,988 
Other3,275 2,418 
$50,872 $47,756 
Deferred tax liabilities:
Expensing of housekeeping supplies$(2,174)$(2,351)
Amortization of goodwill and intangibles(3,861)(3,000)
Depreciation of property and equipment(1,664)(1,688)
Lease right-of-use assets(4,048)(4,571)
Other(955)(920)
$(12,702)$(12,530)
Net deferred tax assets$38,170 $35,226 

Realization of the Company’s deferred tax assets is dependent upon future earnings in specific tax jurisdictions, the timing and amount of which are uncertain. Management assesses the Company’s income tax positions and records tax benefits for all years subject to examination based upon an evaluation of the facts, circumstances and information available at the reporting dates, which include historical operating results and expectations of future earnings. As such, management believes it is more likely than not that the deferred tax assets recorded will be realized to reduce future income taxes and therefore no valuation allowances are necessary.

The table below provides a reconciliation between the tax expense computed by applying the statutory federal income tax rate to income before income taxes and the provision for income taxes:
 Year Ended December 31,
 202420232022
(in thousands)
Income tax expense computed at statutory rate$11,118 $11,182 $9,356 
Increases (decreases) resulting from:
State income taxes, net of federal tax benefit2,631 4,153 2,594 
Federal jobs credits(1,914)(2,014)(2,571)
Tax exempt interest(306)(348)(308)
Share-based compensation1,722 1,610 1,250 
Fines and penalties18 55 4 
Other, net201 32 (15)
Income tax expense$13,470 $14,670 $10,310 

The Company performs an evaluation each period of its tax positions taken and expected to be taken in tax returns. The evaluation is performed on positions relating to tax years that remain subject to examination by major tax jurisdictions, the earliest of which is the tax year ended December 31, 2019. Based on the evaluation, the Company concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. Therefore, the table reporting on the change in the liability for unrecognized tax benefits during the years ended December 31, 2024 and 2023 is omitted as there is no activity to report in such account for the years ended December 31, 2024 or 2023.
v3.25.0.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information
Note 12 — Segment Information

The Company manages and evaluates its operations in two reportable segments: Housekeeping (housekeeping, laundry, linen and other services) and Dietary (dietary department services). Although both segments serve a similar customer base and share many operational similarities, they are managed separately due to distinct differences in the type of services provided, as well as the specialized expertise required of the professional management personnel responsible for delivering each segment’s services. Such services are rendered pursuant to discrete contracts, specific to each reportable segment.

In 2024, the Company adopted ASU 2023-07. ASU 2023-07 created certain additional disclosure requirements, including, among other requirements, a disclosure of the Company’s Significant Segment Expenses (“SSEs”) regularly provided to the Company’s Chief Operating Decision Maker (“CODM”) included within each reported measure of segment profit or loss, a required disclosure for other segment items and a narrative description of such items, a disclosure of the title and the position of the CODM and a narrative disclosure describing how the CODM uses the reported segment profit or loss measures to assess segment performance and allocate resources.

The CODM for both segments for each of the years ended December 31, 2024, 2023, and 2022 was Theodore Wahl, the Company’s President and Chief Executive Officer. As part of the adoption of ASU 2023-07, management reviewed the information provided to the CODM and updated the presentation of such information, including SSEs, to better align with the requirements of ASU 2023-07. Certain prior period segment information has been recast in order to conform with current-period presentation requirements, including the allocation methodology of bad debt expense, labor and labor-related costs and certain other segment items to segments. Additionally, the Company’s CODM does not review assets by segment to assess segment performance or allocate resources, nor is such information provided to the CODM. Accordingly, the Company does not present assets by segment.

The Company’s SSEs for each segment include direct labor costs and segment-based management expenses (collectively, “labor and labor-related”), food, chemicals and supplies, bad debt expense, and depreciation & amortization, as these are specific costs regularly provided to the CODM and used to evaluate segment performance. Other segment items include expenses recorded within costs of services provided which are not regularly provided to the CODM. The CODM evaluates segment profit each period against historical results, factoring in macroeconomic factors such as the cost of labor and supplies, to assess segment performance.

The Company’s accounting policies for the segments are generally the same as described in the Company’s significant accounting policies. The Company does not allocate Corporate expenses, gains (losses) on deferred compensation plan investments, other (income) expense, net, interest expense and income tax provision to segments; such amounts are added to combined segment profit and reconciled to the Company’s consolidated income before income taxes. All revenues and net income are earned in the United States.
The following tables provide profit information disaggregated by the Company’s reportable segments for each of the years ended December 31, 2024, 2023, and 2022:

Year Ended December 31, 2024
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$765,368 $950,314 $1,715,682 
Significant Segment Expenses
Labor and labor-related1
600,198 537,446 1,137,644 
Food, chemicals and supplies56,504 308,859 365,363 
Bad debt expense14,101 32,659 46,760 
Depreciation and amortization expense3,701 2,856 6,557 
Other segment items2
15,454 22,473 37,927 
Segment profit$75,410 $46,021 $121,431 
Segment margin9.9 %4.8 %
Unallocated expenses (income)
Corporate expenses3
$68,160 
Gain on deferred compensation plan investments8,241 
Other (income), net(14,349)
Interest expense6,438 
Income before income taxes$52,941 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.
Year Ended December 31, 2023
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$766,651 $904,738 $1,671,389 
Significant Segment Expenses
Labor and labor-related1
599,881 522,052 1,121,933 
Food, chemicals and supplies58,627 294,690 353,317 
Bad debt expense17,557 18,046 35,603 
Depreciation and amortization expense3,664 3,779 7,443 
Other segment items2
14,907 21,446 36,353 
Segment profit$72,015 $44,725 $116,740 
Segment margin9.4 %4.9 %
Unallocated expenses (income)
Corporate expenses3
$62,082 
Gain on deferred compensation plan investments6,684 
Other (income), net(12,938)
Interest expense7,856 
Income before income taxes$53,056 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.

Year Ended December 31, 2022
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$795,687 $894,489 $1,690,176 
Significant Segment Expenses
Labor and labor-related1
621,469 534,786 1,156,255 
Food, chemicals and supplies63,300 288,975 352,275 
Bad debt expense11,823 20,146 31,969 
Depreciation and amortization4,040 4,528 8,568 
Other segment items2
14,427 19,675 34,102 
Segment profit$80,628 $26,379 $107,007 
Segment margin10.1 %2.9 %
Unallocated expenses (income)
Corporate expenses3
$63,218 
Loss on deferred compensation plan investments(9,178)
Other expense, net5,427 
Interest expense2,987 
Income before income taxes$44,553 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.
The following table provides capital expenditures disaggregated by the Company’s reportable segments for each of the years ended December 31, 2024, 2023, and 2022:

Year Ended December 31,
202420232022
(in thousands)
Capital expenditures
Housekeeping$5,166 $4,684 $4,412 
Dietary936 494 499 
Corporate overhead234 228 299 
Consolidated$6,336 $5,406 $5,210 
v3.25.0.1
Basic Earnings Per Common Share
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Basic Earnings Per Common Share
Note 13 — Basic Earnings Per Common Share

Basic and diluted earnings per common share are computed by dividing net income by the weighted-average number of basic and diluted common shares outstanding, respectively. The weighted-average number of diluted common shares includes the impact of dilutive securities, including outstanding stock options and unvested restricted stock units. The table below reconciles the weighted-average basic and diluted common shares outstanding for 2024, 2023 and 2022:

Year Ended December 31,
202420232022
Numerator for basic and diluted earnings per share:
Net income$39,471 $38,386 $34,243 
Denominator:
Weighted average number of common shares outstanding - basic73,754 74,288 74,336 
Effect of dilutive securities1
234 52 15 
Weighted average number of common shares outstanding - diluted73,988 74,340 74,351 
Basic earnings per share:$0.54 $0.52 $0.46 
Diluted earnings per share:$0.53 $0.52 $0.46 
1.Certain outstanding equity awards are anti-dilutive and therefore were excluded from the calculation of the weighted-average number of diluted common shares outstanding.

Anti-dilutive outstanding equity awards under share-based compensation plans were as follows:

Year Ended December 31,
202420232022
(in thousands)
Anti-dilutive equity awards2,788 3,228 3,203 
v3.25.0.1
Other Contingencies
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Other Contingencies
Note 14 — Other Contingencies

Line of Credit

At December 31, 2024, the Company had a $300.0 million bank line of credit on which to draw for general corporate purposes. Amounts drawn under the line of credit generally bear interest at a floating rate, based on the Company’s leverage ratio, and starting at the Term Secured Overnight Financing Rate (“SOFR”) plus 165 basis points. The Company did not have any borrowings under the line of credit as of December 31, 2024, and as of December 31, 2023 there were $25.0 million of borrowings under the line of credit at an effective interest rate of 7.26%. The line of credit requires the Company to satisfy two financial covenants, with which the Company is in compliance as of December 31, 2024. The line of credit expires on November 22, 2027. The Company’s line of credit was amended on November 22, 2022 to, among other things, provide for a five-year unsecured revolving loan facility in the aggregate amount of $300 million with, at the Company’s option, the ability to increase the revolving loan commitments to an aggregate amount not to exceed $500 million.

At December 31, 2024, the Company had outstanding $50.8 million in irrevocable standby letters of credit, which relate to payment obligations under the Company’s insurance programs. In connection with the issuance of the letters of credit, the amount available under the line of credit was reduced by $50.8 million to $249.2 million at December 31, 2024. On December 24, 2024, January 16, 2025 and January 22, 2025, the letters of credit were renewed, and they all expire in the first quarter of 2026.

Tax Jurisdictions and Matters

The Company provides services throughout the continental United States and is subject to numerous state and local taxing jurisdictions. In the ordinary course of business, a jurisdiction may contest the Company’s reporting positions with respect to the application of its tax code to the Company’s services, which could result in additional tax liabilities.

The Company has tax matters with various taxing authorities. Because of the uncertainties related to both the probable outcomes and amount of probable assessments due, the Company is unable to make a reasonable estimate of a liability. The Company does not expect the resolution of any of these matters, taken individually or in the aggregate, to have a material adverse effect on the consolidated financial position or results of operations based on the Company’s best estimate of the outcomes of such matters.

Legal Proceedings

The Company is subject to various claims and legal actions in the ordinary course of business and records legal expenses as they are incurred. Some of these matters include payroll- and employee-related matters and examinations by governmental agencies. As the Company becomes aware of such claims and legal actions, the Company records accruals for any exposures that are probable and estimable. If adverse outcomes of such claims and legal actions are reasonably possible, Management assesses materiality and provides financial disclosure, as appropriate.

At this time, the Company is unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote with respect to certain pending litigation claims asserted and it is not currently possible to assess whether or not the outcome of these proceedings may have a material adverse effect on the Company.

Government Regulations

The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payers’ reimbursement funding rates. New legislation or additional changes in existing regulations could directly impact the governmental reimbursement programs in which the customers participate.
v3.25.0.1
Other Employee Benefit Plans
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Other Employee Benefit Plans
Note 15 — Other Employee Benefit Plans

Retirement Savings Plan

Since October 1, 1999, the Company has had a retirement savings plan for eligible employees (the “RSP”) under Section 401(k) of the Internal Revenue Code. The RSP allows eligible employees to contribute up to 15% of their eligible compensation on a pre-tax basis.
v3.25.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions
Note 16 — Related Party Transactions

During the year ended December 31, 2024, the Company invested in Align+Engage LLC, a health care technology company which specializes in the long-term and acute care markets, which is accounted for as an equity method investment. During the year ended December 31, 2024, the Company incurred costs of $0.6 million in connection with work performed by Align+Engage LLC on an application to be used by Company personnel.

For the years ended December 31, 2023 and 2022, the Company did not have any material related party transactions.
v3.25.0.1
Accrued Insurance Claims
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Accrued Insurance Claims
Note 17— Accrued Insurance Claims

The Company currently has a Paid Loss Retrospective Insurance Plan for general liability, workers’ compensation, auto and other self-insurance programs, which comprised approximately 25.4% and 25.3% of the Company’s liabilities at December 31, 2024 and 2023, respectively. Under the Company’s insurance plans, predetermined loss limits are arranged with the Company’s insurance company to limit both per occurrence cash outlay and annual insurance plan cost. The Company’s accounting for this plan utilizes current valuations from a third-party actuary, which include assumptions based on data such as historical claims, pay-out experience, demographic factors, industry trends, severity factors and other actuarial calculations. In the event that the Company’s claims experience and/or industry trends result in an unfavorable change in the assumptions or outcomes, it would have an adverse effect on the Company’s results of operations and financial condition.

For general liability, workers’ compensation, auto and other self-insurance programs, the Company records both a reserve for the estimated future cost of claims and related expenses that have been reported but not settled, as well as an estimate of claims incurred but not reported. General liability and workers’ compensation reserves for claims incurred but not reported are developed by a third party actuary through review of the Company’s historical data and open claims.

In 2024, self-insurance liabilities decreased due to favorable $11.6 million adjustments after considering updated actuarial estimates for projected incurred losses on past claims. In 2023, self-insurance liabilities decreased due to a favorable $12.5 million adjustment after considering updated actuarial estimates for projected incurred losses on past claims. Such estimates declined in 2024 due to favorable claim experience and loss mitigation efforts.
v3.25.0.1
Treasury Stock
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Treasury Stock
Note 18 — Treasury Stock

On February 14, 2023, our Board of Directors authorized the repurchase of up to 7.5 million outstanding shares of common stock. Pursuant to the Repurchase Plan, the Company repurchased 0.4 million shares of the Company’s common stock during the year ended December 31, 2024 for a total cost of $5.0 million inclusive of transaction costs. For the year ended December 31, 2023, the Company purchased 1.0 million shares of the Company's common stock for a total cost of $11.1 million inclusive of transaction costs.
v3.25.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events
Note 19 — Subsequent Events

The Company evaluated all subsequent events through the filing date of this Annual Report on Form 10-K. There were no events or transactions occurring during this subsequent reporting period which require recognition or additional disclosure in these financial statements.
v3.25.0.1
Schedule II - Valuation and Qualifying Accounts and Reserves
 12 Months Ended
Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts and Reserves
Schedule II — Valuation and Qualifying Accounts and Reserves
DescriptionBeginning BalanceCharged to Costs and ExpensesDeductionsEnding Balance
(in thousands)
2024
Allowance for Doubtful Accounts$91,699 $46,760 $37,677 $100,782 
2023
Allowance for Doubtful Accounts$73,464 $35,604 $17,369 $91,699 
2022
Allowance for Doubtful Accounts$65,584 $31,969 $24,088 $73,464 
v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net income $ 39,471 $ 38,386 $ 34,243
v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.0.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management and Strategy

The Company adopted an Information Security Policy which governs the Company’s management of information technology (“IT”) systems, network, information, data and assets. HCSG’s Information Security Policy is periodically reviewed based on the National Institute of Standards and Technology Cybersecurity Framework. The Company regularly monitors and measures the performance of the IT Systems and Assets and the Information Security Policy. HCSG has procedures to ensure that any of its vendors and suppliers that create, utilize or process our data take a similar, risk-based approach to information security.

Management maintains the cybersecurity risk prevention program which includes ongoing employee education and procedures for cybersecurity incident prevention, detection and response. The Company retains third parties, including IT professionals and legal counsel, specializing in cybersecurity risk management to assist in implementing cybersecurity controls. The Company oversees and identifies material risks from cybersecurity threats associated with its use of third-party service providers by reviewing SOC 1 or SOC 2 reports (whichever is more applicable) for key outsourced systems, including all systems which house protected health information or personally identifiable information. The cybersecurity risk prevention program is part of the Company's overall risk management program.

Please refer to the risk factor titled “We have experienced cyber attacks and breaches, and may in the future experience cyber attacks and breaches which could cause operational disruptions, fraud or theft of sensitive information.” in “Risk Factors” in Part I, Item 1A of this Form 10-K for more information on risks posed by cybersecurity threats to the Company.

As previously disclosed in a Form 8-K filed on October 16, 2024, on October 9, 2024 we identified a cybersecurity incident, which involved unauthorized activity within some of our systems. We immediately activated the Company’s Cyber Incident Response Plan (“IRP”) to investigate such activity with the assistance of leading third-party cybersecurity experts. We also notified law enforcement authorities. We continue to monitor the situation and take appropriate actions consistent with our response protocols. As of the date of this filing, the incident has not caused, and is not expected to cause, disruption of the Company’s business operations. And although there can be no assurance, we do not believe the identified cybersecurity incident will have a material effect on our business, financial condition, results of operations or cash flows.

Management’s Role in Assessing and Managing Material Risks from Cybersecurity Threats

The Company’s day-to-day risk management is under the direction of Jason J. Bundick, the Company’s Executive Vice President, Chief Compliance Officer, General Counsel and Secretary. Jason Osbeck, the Company’s Senior Vice President of Information and Technology, is responsible for day-to-day cybersecurity risk management under the direction of Mr. Bundick. Mr. Osbeck has served in this role at the Company since 2012.
The Company has an IRP which details the Company’s policies and procedures in the event of a cyber incident. The Company’s IT department, led by Mr. Osbeck, logs all potential cybersecurity incidents reported which are then reviewed by an Incident Response Team (“IRT”), a cross-functional internal team including IT, risk management, legal and other departmental representation as necessary to identify the potential impact of the cybersecurity incident. As needed, the IRT will consult with third party legal counsel and IT advisory firms to appropriately respond to existing cyber threats. In the event a material incident is identified, the Company will report such incidents in compliance with applicable law. Material cyber events, if any, are reported to the Board of Directors as they occur. Additionally, Mr. Bundick provides quarterly updates to the Audit Committee on all cybersecurity matters during the quarter.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
The Company adopted an Information Security Policy which governs the Company’s management of information technology (“IT”) systems, network, information, data and assets. HCSG’s Information Security Policy is periodically reviewed based on the National Institute of Standards and Technology Cybersecurity Framework. The Company regularly monitors and measures the performance of the IT Systems and Assets and the Information Security Policy. HCSG has procedures to ensure that any of its vendors and suppliers that create, utilize or process our data take a similar, risk-based approach to information security.
Management maintains the cybersecurity risk prevention program which includes ongoing employee education and procedures for cybersecurity incident prevention, detection and response. The Company retains third parties, including IT professionals and legal counsel, specializing in cybersecurity risk management to assist in implementing cybersecurity controls. The Company oversees and identifies material risks from cybersecurity threats associated with its use of third-party service providers by reviewing SOC 1 or SOC 2 reports (whichever is more applicable) for key outsourced systems, including all systems which house protected health information or personally identifiable information. The cybersecurity risk prevention program is part of the Company's overall risk management program.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
Our Board is responsible for overseeing the Company’s risk management process. The Board focuses on the Company’s general risk management strategy, including the most significant risks facing the Company, and ensures that appropriate risk mitigation strategies are implemented by management. The Audit Committee oversees the Company’s cybersecurity risk mitigation efforts. The Audit Committee reports to the full Board as appropriate, including when a matter rises to the level of a material risk.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit Committee reports to the full Board as appropriate, including when a matter rises to the level of a material risk.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The Company has an IRP which details the Company’s policies and procedures in the event of a cyber incident. The Company’s IT department, led by Mr. Osbeck, logs all potential cybersecurity incidents reported which are then reviewed by an Incident Response Team (“IRT”), a cross-functional internal team including IT, risk management, legal and other departmental representation as necessary to identify the potential impact of the cybersecurity incident. As needed, the IRT will consult with third party legal counsel and IT advisory firms to appropriately respond to existing cyber threats. In the event a material incident is identified, the Company will report such incidents in compliance with applicable law. Material cyber events, if any, are reported to the Board of Directors as they occur. Additionally, Mr. Bundick provides quarterly updates to the Audit Committee on all cybersecurity matters during the quarter.
Cybersecurity Risk Role of Management [Text Block]
Management’s Role in Assessing and Managing Material Risks from Cybersecurity Threats

The Company’s day-to-day risk management is under the direction of Jason J. Bundick, the Company’s Executive Vice President, Chief Compliance Officer, General Counsel and Secretary. Jason Osbeck, the Company’s Senior Vice President of Information and Technology, is responsible for day-to-day cybersecurity risk management under the direction of Mr. Bundick. Mr. Osbeck has served in this role at the Company since 2012.
The Company has an IRP which details the Company’s policies and procedures in the event of a cyber incident. The Company’s IT department, led by Mr. Osbeck, logs all potential cybersecurity incidents reported which are then reviewed by an Incident Response Team (“IRT”), a cross-functional internal team including IT, risk management, legal and other departmental representation as necessary to identify the potential impact of the cybersecurity incident. As needed, the IRT will consult with third party legal counsel and IT advisory firms to appropriately respond to existing cyber threats. In the event a material incident is identified, the Company will report such incidents in compliance with applicable law. Material cyber events, if any, are reported to the Board of Directors as they occur. Additionally, Mr. Bundick provides quarterly updates to the Audit Committee on all cybersecurity matters during the quarter.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Jason Osbeck, the Company’s Senior Vice President of Information and Technology, is responsible for day-to-day cybersecurity risk management under the direction of Mr. Bundick. Mr. Osbeck has served in this role at the Company since 2012.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Mr. Osbeck has served in this role at the Company since 2012.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] The Company has an IRP which details the Company’s policies and procedures in the event of a cyber incident. The Company’s IT department, led by Mr. Osbeck, logs all potential cybersecurity incidents reported which are then reviewed by an Incident Response Team (“IRT”), a cross-functional internal team including IT, risk management, legal and other departmental representation as necessary to identify the potential impact of the cybersecurity incident. As needed, the IRT will consult with third party legal counsel and IT advisory firms to appropriately respond to existing cyber threats. In the event a material incident is identified, the Company will report such incidents in compliance with applicable law. Material cyber events, if any, are reported to the Board of Directors as they occur. Additionally, Mr. Bundick provides quarterly updates to the Audit Committee on all cybersecurity matters during the quarter.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.0.1
Description of Business and Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Nature of Operations
Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments of the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, they are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs.
The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.
Segment Information
The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”).

Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility.

Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs.
Principles of Consolidation
The financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the SEC, specifically Regulation S-X and the instructions to Form 10-K. Unless otherwise indicated, all references to years are to the Company’s fiscal year, which ends on December 31.

The accompanying Consolidated Financial Statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates in Financial Statements
In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.
Fair Value of Financial Instruments
The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy.
Assets and liabilities are classified within the fair value hierarchy based on the lowest level (least observable) input that is significant to the measurement in its entirety.

While unobservable inputs reflect the Company’s market assumptions, preference is given to observable inputs. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices for identical instruments in active markets;
Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and
Level 3 – Significant inputs to the valuation model are unobservable
The Company’s financial instruments that are measured at fair value on a recurring basis consist of marketable securities and the deferred compensation fund investments. The carrying value of other financial instruments such as cash and cash equivalents, accounts and short-term notes receivable, accounts payable (including income taxes payable and accrued expenses) and borrowings under the Company’s line of credit approximate their fair values at December 31, 2024 and 2023, due to the short period of time to maturity or repayment.
Cash and Cash Equivalents and Restricted Cash Equivalents
Cash and cash equivalents and restricted cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk. The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits.
Investments in Marketable Securities and Restricted Marketable Securities
Marketable securities are defined as fixed income investments which are highly liquid and can be readily purchased or sold through established markets. As of December 31, 2024 and 2023, the Company had marketable securities of $75.6 million and $93.1 million, respectively, comprised primarily of municipal bonds, U.S. treasury bonds, corporate bonds and other government bonds. These investments are accounted for as available-for-sale securities and are reported at fair value on the Company's Consolidated Balance Sheets. For the year ended December 31, 2024, $0.5 million of unrealized losses related to these investments were recorded in Other comprehensive (loss) income. For the years ended December 31, 2023 and 2022, $1.6 million of unrealized gains and $7.5 million of unrealized losses related to these marketable securities were recorded in Other comprehensive (loss) income, respectively. Unrealized gains and losses are recorded net of income taxes, with any income tax provision or benefit recorded once gains and losses are recognized.

These assets are held by the Company’s wholly-owned captive insurance company subsidiary as required by state insurance regulations. The Company’s investment policy is intended to manage the assets to achieve the goals of preserving principal, maintaining adequate liquidity at all times and maximizing returns subject to investment guidelines. The investment policy limits investment to certain types of instruments issued by institutions primarily with investment grade credit ratings and places restrictions on concentration by type and issuer.
The Company periodically reviews the investments in marketable securities and restricted marketable securities for credit impairment when an investment’s fair value declines below the amortized cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Accounts and Notes Receivable
Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement and range from prepaid to 120 days. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided.

Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. Notes receivable are recorded at face value less any imputed interest assessed. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses.
Allowance for Doubtful Accounts
Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received.
Inventories and Supplies
Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (FIFO) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months.
Revenue Recognition The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the expected value of consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration.
Leases The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direct of use of the asset, and the Company obtains substantially all of the economic benefits from the right of use.
Property and Equipment, Net Property and equipment, with the exception of those pertaining to leases, are stated at cost, net of accumulated depreciation. Additions, renewals and improvements are capitalized, while maintenance and repair costs are expensed when incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in Investment and other income (loss), net on the Consolidated Statements of Comprehensive Income. Depreciation is recorded using the straight-line method over the following estimated useful lives: Housekeeping and Dietary equipment — 3 to 5 years; computer hardware and software — 5 years; and other, consisting of furniture and fixtures, leasehold improvements and vehicles — 5 to 10 years.
Income Taxes
The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not.

Uncertain income tax positions taken or expected to be taken in tax returns are reflected within the Company’s consolidated financial statements based on a recognition and measurement process.

The Company may from time to time be assessed interest or penalties by taxing jurisdictions, although any such assessments historically have been minimal and immaterial to its financial results. When the Company has received an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense. In addition, any interest or penalties relating to recognized uncertain tax positions would also be recorded in selling, general and administrative expense.
Earnings per Common Share
Basic earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock options and upon the vesting of restricted stock units (“RSUs”), deferred stock units (“DSUs”), and performance-based restricted stock units (“PSUs”).
Share-Based Compensation
The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes valuation model for stock options, using a Monte Carlo simulation for PSUs and using the share price on the date of grant for RSUs and DSUs. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive Income over the requisite service periods, with adjustments made for forfeitures as they occur.
Advertising Costs Advertising costs are expensed when incurred.
Impairment of Long-Lived Assets
The carrying amounts of long-lived assets are periodically reviewed to determine whether current events or circumstances warrant adjustment to such carrying amounts. Any impairment would be measured as the amount that the carrying value of such assets exceeds their fair value. Considerable management judgment is necessary to estimate the fair value of assets. Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell. No impairment loss was recognized on the Company’s long-lived assets during the years ended December 31, 2024, 2023 or 2022.
Goodwill and Other Intangible Assets Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. Other intangible assets are amortized on a straight-line basis over their respective useful lives.
Treasury Stock and Authorized Shares of Common Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid-in capital.
On June 18, 2024, the Company amended its Restated Articles of Incorporation to increase the number of authorized shares of common stock available for issuance from 100 million to 200 million, as approved by the requisite vote of the Company’s shareholders.
Investments in Equity Securities
The Company accounts for investments in equity securities using the equity method when the Company determines that it can exercise significant influence over the investee. The Company accounts for investments in equity securities at fair value when the Company determines that it cannot exercise significant influence over the investee. During the year ended December 31, 2024, the Company invested $2.8 million for a 25% ownership share in a health care technology company which specializes in the long-term and acute care markets which was accounted for as an equity method investment. Investments in equity securities are recorded within “Other long-term assets” in the Company’s Consolidated Balance Sheets. The Company’s proportionate share of earnings or losses of the investee are recorded within “Investment and other income, net” on the Company’s Consolidated Statements of Comprehensive Income. The Company elects to record its proportionate share of earnings or losses in equity method investments using a three-month lag based on the most recently available financial statements.
Concentrations of Credit Risk
The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, restricted cash equivalents, marketable securities, restricted marketable securities, deferred compensation funding and accounts and notes receivable. At December 31, 2024 and 2023, the majority of the Company’s cash and cash equivalents, restricted cash equivalents, marketable securities and restricted marketable securities were held in two large financial institution located in the United States. The Company’s marketable securities and restricted marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s deferred compensation funding consists of fund and money market investments all of which are highly liquid and held in a trust account.

The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until such new legislation or changes in existing regulations are fully implemented and governmental agencies issue applicable regulations or guidance.
Although the Company negotiates the pricing and other terms for the majority of our purchases of food and dining supplies directly with national manufacturers, the Company procures more than 50% of these products and other items through Sysco Corporation (“Sysco”). Sysco is responsible for tracking the Company’s orders and delivering products to the Company’s customer locations.
Significant Customer
For the years ended December 31, 2024, 2023 and 2022, Genesis Healthcare, Inc. (“Genesis”) accounted for $148.9 million or 8.7%, $181.4 million or 10.9% and $169.1 million or 10.0% of the Company’s consolidated revenues, respectively. As of December 31, 2024, the Company had outstanding accounts receivable and notes receivable of $46.1 million and $21.9 million, respectively, from Genesis. Although the Company expects to continue its relationship with Genesis, there can be no assurance thereof. Revenues generated from Genesis were included in both operating segments previously mentioned. Any extended discontinuance of revenues, or significant reduction, from this customer could, if not replaced, have a material impact on our operations. In addition, if Genesis fails to abide by current payment terms it could increase our accounts receivable balance and have a material adverse effect on our financial condition, results of operations, and cash flows. No other single customer or customer group represented more than 10% of consolidated revenues for the years ended December 31, 2024, 2023 and 2022.
Reclassification
Prior period line items in the Consolidated Balance Sheets and the Consolidated Statements of Stockholders’ Equity have been revised to conform with current period presentation.
Recent Accounting Pronouncements
In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The Company adopted ASU 2023-07 for the annual period ended December 31, 2024. Refer to Note 12 — Segment Information herein for further information.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances effective tax rate reconciliation disclosure requirements and provides clarity to the disclosures of income taxes paid, income before taxes and provision for income taxes. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which amends the codification to enhance disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments are effective for fiscal years beginning after December 15, 2026. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company’s present or future consolidated financial statements.
Employee Retention Credit
On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021.
The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021. Through February 14, 2025, the Company has been informed only that the IRS review of the ERC has been delayed, and no refunds or other material updates from the IRS regarding the ERC filing have been received. The Company believes that there is not reasonable assurance that any receipt of credits and compliance with the terms of the ERC will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” in the Consolidated Statements of Comprehensive Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations.
v3.25.0.1
Description of Business and Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents
The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows.

December 31, 2024December 31, 2023December 31, 2022
(in thousands)
Cash and cash equivalents$56,776 $54,330 $26,279 
Restricted cash equivalents1
3,355 — — 
Total cash and cash equivalents and restricted cash equivalents$60,131 $54,330 $26,279 
1.On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of December 31, 2024. The trust account was set up in conjunction with a reduction in the Company’s letters of credit collateral obligation for insurance obligations.
Schedule of Restricted Cash Equivalents
The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows.

December 31, 2024December 31, 2023December 31, 2022
(in thousands)
Cash and cash equivalents$56,776 $54,330 $26,279 
Restricted cash equivalents1
3,355 — — 
Total cash and cash equivalents and restricted cash equivalents$60,131 $54,330 $26,279 
1.On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of December 31, 2024. The trust account was set up in conjunction with a reduction in the Company’s letters of credit collateral obligation for insurance obligations.
v3.25.0.1
Accounts and Notes Receivable (Tables)
 12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Schedule of Accounts and Notes Receivable
The Company’s accounts and notes receivable balances consisted of the following as of December 31, 2024, 2023 and 2022:

December 31, 2024December 31, 2023December 31, 2022
(in thousands)
Short-term
Accounts receivable$418,427 $425,681 $375,225 
Allowance for doubtful accounts, accounts receivable(87,520)(80,817)(66,601)
Total net accounts receivable$330,907 $344,864 $308,624 
Notes receivable — short–term portion61,801 45,078 31,744 
Allowance for doubtful accounts, notes receivable — short–term portion(10,372)(6,433)(3,591)
Total net notes receivable — short–term portion$51,429 $38,645 $28,153 
Long-term
Notes receivable$43,944 $29,281 $35,882 
Allowance for doubtful accounts(2,890)(4,449)(3,273)
Total net long-term notes receivable$41,054 $24,832 $32,609 
Total net accounts and notes receivable$423,390 $408,341 $369,386 
v3.25.0.1
Allowance for Doubtful Accounts (Tables)
 12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Schedule of Notes Receivable Disaggregated by Vintage Year
The following tables present the Company’s three tiers of notes receivable for the years ended December 31, 2024 and 2023, respectively, further disaggregated by year of origination, as well as write-off activity:

Notes Receivable as of December 31, 2024
Amortized Cost Basis by Origination Year
20242023202220212020PriorTotal
(in thousands)
Notes Receivable
Standard notes receivable$53,592 $7,282 $15,743 $— $— $— $76,617 
Delinquent notes receivable$499 $1,055 $1,942 $671 $— $21,933 $26,100 
Elevated risk notes receivable$— $1,537 $— $— $1,491 $— $3,028 
Current-period gross write-offs$— $742 $483 $3,024 $— $26 $4,275 
Current-period recoveries— — — — — — — 
Current-period net write-offs $— $742 $483 $3,024 $— $26 $4,275 
Notes Receivable as of December 31, 2023
Amortized Cost Basis by Origination Year
20232022202120202019PriorTotal
(in thousands)
Notes Receivable
Standard notes receivable1
$18,175 $25,505 $855 $1,529 $3 $21,033 $67,100 
Elevated risk notes receivable$— $— $7,259 $— $— $— $7,259 
Current-period gross write-offs$— $189 $— $— $50 $2,253 $2,492 
Current-period recoveries— — — — — — — 
Current-period net write-offs$— $189 $— $— $50 $2,253 $2,492 
1.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
Schedule of Age Analysis of Past-Due Note Receivable
The following tables provide information as to the status of payment on the Company’s gross notes receivable which were past due as of December 31, 2024 and 2023, respectively:

 Age Analysis of Past-Due Notes Receivable as of December 31, 2024
0-90 Days91 - 180 DaysGreater than 181 DaysTotal
(in thousands)
Notes Receivable
Standard notes receivable$142 $— $— $142 
Delinquent notes receivable1
761 682 23,151 24,594 
Elevated risk notes receivable225 225 2,429 2,879 
$1,128 $907 $25,580 $27,615 
1.Included within the Delinquent notes receivable past-due balance is the entire balance of notes receivable due from Genesis.

Age Analysis of Past-Due Notes Receivable as of December 31, 2023
0-90 Days91 - 180 DaysGreater than 181 DaysTotal
(in thousands)
Notes Receivable
Standard notes receivable1
$3,851 $4,852 $6,914 $15,617 
Elevated risk notes receivable569 569 949 2,087 
$4,420 $5,421 $7,863 $17,704 
1.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
Schedule of Accounts Receivable, Allowance for Doubtful Accounts
The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2024 and 2023, respectively:
Allowance for doubtful accounts
Portfolio Segment:December 31,
2023
Reclassifications1
Write-Offs2
Bad Debt ExpenseDecember 31,
2024
(in thousands)
Accounts receivable$80,819 $— $(33,402)$40,103 $87,520 
Notes receivable
Standard notes receivable$6,125 $(2,615)$— $1,586 $5,096 
Delinquent notes receivable1
— 2,615 (1,252)4,663 6,026 
Elevated risk notes receivable4,755 — (3,023)408 2,140 
Total notes receivable$10,880 $— $(4,275)$6,657 $13,262 
Total accounts and notes receivable$91,699 $— $(37,677)$46,760 $100,782 
1.Delinquent notes receivable were identified as a new loss pool during the year ended December 31, 2024.
2.Write-offs are shown net of recoveries. During the year ended December 31, 2024, the Company collected $0.1 million of accounts receivables that were recovered subsequent to being written-off.
Allowance for doubtful accounts
Portfolio Segment:December 31,
2022
Write-Offs1
Bad Debt ExpenseDecember 31,
2023
(in thousands)
Accounts receivable$66,601 $(14,877)$29,095 $80,819 
Notes receivable
Standard notes receivable2
$6,052 $(1,646)$1,719 $6,125 
Elevated risk notes receivable811 (846)4,790 4,755 
Total notes receivable$6,863 $(2,492)$6,509 $10,880 
Total accounts and notes receivable$73,464 $(17,369)$35,604 $91,699 
1.Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off.
2.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
Schedule of Allowance for Doubtful Accounts
The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2024 and 2023, respectively:
Allowance for doubtful accounts
Portfolio Segment:December 31,
2023
Reclassifications1
Write-Offs2
Bad Debt ExpenseDecember 31,
2024
(in thousands)
Accounts receivable$80,819 $— $(33,402)$40,103 $87,520 
Notes receivable
Standard notes receivable$6,125 $(2,615)$— $1,586 $5,096 
Delinquent notes receivable1
— 2,615 (1,252)4,663 6,026 
Elevated risk notes receivable4,755 — (3,023)408 2,140 
Total notes receivable$10,880 $— $(4,275)$6,657 $13,262 
Total accounts and notes receivable$91,699 $— $(37,677)$46,760 $100,782 
1.Delinquent notes receivable were identified as a new loss pool during the year ended December 31, 2024.
2.Write-offs are shown net of recoveries. During the year ended December 31, 2024, the Company collected $0.1 million of accounts receivables that were recovered subsequent to being written-off.
Allowance for doubtful accounts
Portfolio Segment:December 31,
2022
Write-Offs1
Bad Debt ExpenseDecember 31,
2023
(in thousands)
Accounts receivable$66,601 $(14,877)$29,095 $80,819 
Notes receivable
Standard notes receivable2
$6,052 $(1,646)$1,719 $6,125 
Elevated risk notes receivable811 (846)4,790 4,755 
Total notes receivable$6,863 $(2,492)$6,509 $10,880 
Total accounts and notes receivable$73,464 $(17,369)$35,604 $91,699 
1.Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off.
2.The Company did not identify delinquent notes receivable as a separate loss pool during the year ended December 31, 2023.
v3.25.0.1
Changes in Accumulated Other Comprehensive Loss by Component (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Loss The following tables provide a summary of the changes in accumulated other comprehensive loss, net of taxes:
Unrealized Gains and (Losses) on Available-for-Sale Securities1
Year Ended December 31,
202420232022
(in thousands)
Accumulated other comprehensive (loss) income — beginning balance$(1,844)$(3,477)$4,000 
Other comprehensive (loss) income before reclassifications(753)1,624 (7,505)
Losses reclassified from other comprehensive (loss) income²280 9 28 
Net current period other comprehensive (loss) income³(473)1,633 (7,477)
Accumulated other comprehensive loss — ending balance$(2,317)$(1,844)$(3,477)
1.All amounts are net of tax.
2.Realized gains and losses were recorded pre-tax under “Investment and other income (loss), net” in the Consolidated Statements of Comprehensive Income. For the year ended December 31, 2024, the Company recorded $0.4 million of realized losses from the sale of available-for-sale securities. For the years ended December 31, 2023 and 2022, the Company recorded less than $0.1 million of realized losses from the sale of available-for-sale securities. Refer to Note 9 — Fair Value Measurements herein for further information.
3.For the year ended December 31, 2024, the change in accumulated other comprehensive loss was net of a tax benefit of $0.1 million. For the years ended December 31, 2023 and 2022, the changes in accumulated other comprehensive loss were net of a tax expense of $0.4 million and benefit of $2.0 million, respectively.
Schedule of Reclassification out of Accumulated Other Comprehensive Income
Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income
Year Ended December 31,
202420232022
(in thousands)
Losses from the sale of available-for-sale securities$(355)$(12)$(37)
Tax benefit75 3 9 
Net loss reclassified from accumulated other comprehensive income$(280)$(9)$(28)
v3.25.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
The following table sets forth the amounts of property and equipment by each class of depreciable asset as of December 31, 2024 and December 31, 2023:
December 31, 2024December 31, 2023
(in thousands)
Housekeeping and Dietary equipment$17,052 $15,764 
Computer hardware and software8,196 6,870 
Operating lease — right-of-use assets29,669 27,099 
Other1
904 1,070 
Total property and equipment, at cost55,821 50,803 
Less accumulated depreciation2
27,623 22,029 
Total property and equipment, net$28,198 $28,774 
1.Includes furniture and fixtures, leasehold improvements and autos and trucks.
2.Includes $13.2 million and $9.4 million related to accumulated depreciation on Operating lease – right-of-use assets as of December 31, 2024 and 2023, respectively.
v3.25.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Schedule of Components of Lease Expense
Components of lease expense are presented below for the years ended December 31, 2024, 2023 and 2022.

Year Ended December 31,
202420232022
(in thousands)
Lease cost
Operating lease cost$7,799 $6,400 $5,673 
Short-term lease cost883 1,037 1,265 
Variable lease cost1,609 1,952 857 
Total lease cost$10,291 $9,389 $7,795 
Schedule of Supplemental Information Required by ASC 842
Supplemental information is presented below for the years ended December 31, 2024, 2023 and 2022.

Year Ended December 31,
202420232022
(dollar amounts in thousands)
Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$8,125$6,808$6,385
ROU Assets obtained in exchange for lease obligations3,7216,0641,650
Weighted-average remaining lease term — operating leases2.6 years3.3 years4.2 years
Weighted-average discount rate — operating leases6.3 %6.6 %4.4 %
Schedule of Future Minimum Lease Payments
The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of December 31, 2024:

Period/YearOperating Leases
(in thousands)
2025$8,420 
20265,746 
20272,264 
20281,389 
2029116 
Thereafter— 
Total minimum lease payments$17,935 
Less: imputed lease payments1,480 
Present value of lease liabilities$16,455 
v3.25.0.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table sets forth the amounts of goodwill by reportable segment as of December 31, 2024 and 2023:
December 31, 2024December 31, 2023
(in thousands)
Housekeeping$42,377 $42,377 
Dietary33,152 33,152 
Total Goodwill$75,529 $75,529 
Schedule of Intangible Assets The following table sets forth the amounts of other intangible assets as of December 31, 2024 and 2023:
December 31, 2024December 31, 2023
Gross AmountAccumulated AmortizationNet AmountGross AmountAccumulated AmortizationNet Amount
(in thousands)
Customer relationships$45,634 $38,093 $7,541 $45,634 $35,718 $9,916 
Trade names1,731 466 1,265 1,731 329 1,402 
Patents1,086 505 581 1,086 369 717 
Non-compete agreements233 178 55 233 141 92 
Total other intangible assets$48,684 $39,242 $9,442 $48,684 $36,557 $12,127 
Schedule of Estimated Amortization Expense For Intangibles Subject To Amortization
The following table sets forth the estimated amortization expense for intangibles subject to amortization for 2025, the following four fiscal years and thereafter:
Period/YearTotal Amortization Expense
(in thousands)
2025$2,685 
2026$2,666 
2027$1,195 
2028$613 
2029$509 
Thereafter$1,774 
Total$9,442 
v3.25.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Contractual Maturities of Debt Securities
The following table summarizes the contractual maturities of debt securities held as of December 31, 2024 and 2023 which are classified within “Marketable securities, at fair value” and “Restricted marketable securities, at fair value” in the Consolidated Balance Sheets:
Debt Securities — Available-for-Sale
Contractual maturity:December 31, 2024December 31, 2023
(in thousands)
Marketable securities, at fair value
Maturing in one year or less$653 $6,324 
Maturing in second year through fifth year23,341 34,939 
Maturing in sixth year through tenth year13,113 39,309 
Maturing after ten years13,428 12,559 
Total marketable securities, at fair value$50,535 $93,131 
Restricted marketable securities, at fair value
Maturing in one year or less$2,474 $— 
Maturing in second year through fifth year15,774 — 
Maturing in sixth year through tenth year5,837 — 
Maturing after ten years1,020 — 
Total restricted marketable securities, at fair value$25,105 $— 
Total debt securities — available-for-sale$75,640 $93,131 
Schedule of Fair Value Measurements
The following tables provide fair value measurement information for the Company’s financial assets, including marketable securities, restricted marketable securities and deferred compensation fund investments as of December 31, 2024 and 2023:

As of December 31, 2024
Fair Value Measurement Using:
(amounts in thousands)Carrying AmountTotal Fair ValueQuoted Prices in Active Markets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Marketable securities
Municipal bonds — taxable$9,600 $9,600 $— $9,600 $— 
Municipal bonds — non-taxable40,935 40,935 — 40,935 — 
Total marketable securities$50,535 $50,535 $— $50,535 $— 
Restricted marketable securities
U.S. treasury bonds$7,309 $7,309 $— $7,309 $— 
U.S. government agency bonds1,218 1,218 — 1,218 — 
International fixed income bonds652 652 — 652 — 
Corporate bonds6,796 6,796 — 6,796 — 
Municipal bonds — taxable9,130 9,130 — 9,130 — 
Total restricted marketable securities$25,105 $25,105 $— $25,105 $— 
Deferred compensation plan
Money market1
$1,961 $1,961 $— $1,961 $— 
Commodities295 295 295 — — 
Fixed income4,417 4,417 4,417 — — 
International4,999 4,999 4,999 — — 
Large cap blend6,669 6,669 6,669 — — 
Large cap growth18,524 18,524 18,524 — — 
Large cap value6,964 6,964 6,964 — — 
Mid cap blend3,957 3,957 3,957 — — 
Real estate372 372 372 — — 
Small cap blend2,980 2,980 2,980 — — 
Deferred compensation plan2
$51,138 $51,138 $49,177 $1,961 $— 
As of December 31, 2023
Fair Value Measurement Using:
(amounts in thousands)Carrying
Amount		Total Fair
Value		Quoted Prices in Active Markets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Marketable securities
Municipal bonds — non-taxable$93,131 $93,131 $— $93,131 $— 
Deferred compensation plan
Money market1
$2,007 $2,007 $— $2,007 $— 
Commodities298 298 298 — — 
Fixed income4,254 4,254 4,254 — — 
International4,621 4,621 4,621 — — 
Large cap blend5,053 5,053 5,053 — — 
Large cap growth13,886 13,886 13,886 — — 
Large cap value5,964 5,964 5,964 — — 
Mid cap blend3,192 3,192 3,192 — — 
Real estate374 374 374 — — 
Small cap blend2,664 2,664 2,664 — — 
Deferred compensation plan2
$42,313 $42,313 $40,306 $2,007 $— 
1.The fair value of the money market is based on the NAV of the shares held by the plan at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment.
2.The deferred compensation plan carrying amounts and total fair value amounts as of December 31, 2024 and 2023 are inclusive of $1.5 million each of holdings expected to be paid to former employees within the next twelve months which were recorded under Prepaid expenses and other assets in the Company’s Consolidated Balance Sheets.
The following table shows the amortized cost, unrealized gains and losses, and estimated fair value of the Company’s debt securities as of December 31, 2024 and 2023:
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Credit Impairment Losses1
December 31, 2024(in thousands)
Type of security:
Marketable securities
Municipal bonds — taxable$10,276 $— $(676)$9,600 $— 
Municipal bonds — non-taxable43,255 — (2,320)40,935 — 
Total marketable securities$53,531 $— $(2,996)$50,535 $— 
Restricted marketable securities
U.S. treasury bonds$7,276 $38 $(5)$7,309 
U.S. government agency bonds1,208 10 — 1,218 
International fixed income bonds647 5 — 652 
Corporate bonds6,780 30 (14)6,796 
Municipal bonds — taxable9,131 40 (41)9,130 
Total restricted marketable securities$25,042 $123 $(60)$25,105 $— 
Total debt securities — available-for-sale$78,573 $123 $(3,056)$75,640 $— 
December 31, 2023
Type of security:
Municipal bonds — non-taxable$95,466 $387 $(2,722)$93,131 $— 
Total debt securities — available-for-sale$95,466 $387 $(2,722)$93,131 $— 
v3.25.0.1
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
The components of the Company’s share-based compensation expense for the years ended December 31, 2024, 2023 and 2022 are as follows:
Year Ended December 31,
202420232022
(in thousands)
Stock options$708 $969 $1,253 
Restricted stock units and deferred stock units6,870 6,657 6,972 
Performance stock units1,341 1,210 819 
Employee Stock Purchase Plan246 149 170 
Total pre-tax share-based compensation expense charged against income$9,165 $8,985 $9,214 
Total recognized tax deficiency related to share-based compensation$(607)$(773)$(783)
The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023 and 2022:

Year Ended December 31,
202420232022
(in thousands)
Selling, general and administrative expense$9,086 $8,942 $9,160 
Costs of services provided79 43 54 
Total share-based compensation expense$9,165 $8,985 $9,214 
Schedule of Other Information of Stock Option Plans
A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023 and changes during the year ended December 31, 2024 are as follows:
Stock Options Outstanding
Number of SharesWeighted Average Exercise Price
(in thousands)
December 31, 20232,438 $30.43 
Granted290 $10.36 
Exercised— $— 
Forfeited(1)$24.43 
Expired(199)$29.12 
December 31, 20242,528 $28.23 
Schedule of Assumption For Fair Value of Options Granted
The fair value of stock option awards granted in 2024, 2023 and 2022 were estimated on the dates of grant using the Black-Scholes option valuation model with the following assumptions:
Year Ended December 31,
202420232022
Risk-free interest rate3.9 %4.0 %1.5 %
Weighted average expected life7.0 years6.9 years6.7 years
Expected volatility40.5 %39.5 %36.6 %
Dividend yield— %— %4.6 %
Schedule of Information of Stock Options Outstanding
The following table summarizes other information about the stock options at December 31, 2024:
December 31, 2024
(amounts in thousands, except per share data)
Outstanding:
Aggregate intrinsic value$0.4 
Weighted average remaining contractual life4.5 years
Exercisable:
Number of options1,737 
Weighted average exercise price$33.91 
Aggregate intrinsic value$— 
Weighted average remaining contractual life3.0 years
Schedule of Restricted Stock Units and Deferred Stock Units
A summary of the outstanding RSUs and DSUs as of December 31, 2023 and changes during the year ended December 31, 2024 is as follows:
Restricted Stock Units & Deferred Stock Units
NumberWeighted Average Grant Date Fair Value
(in thousands)
December 31, 20231,102 $18.57 
Granted775 $10.39 
Vested(298)$21.68 
Forfeited(63)$13.56 
December 31, 20241,516 $13.98 
Schedule of Weighted Average Grant-Date Fair Values and Intrinsic Values of Options Vested
The weighted average grant-date fair values and total fair values of RSUs vested during 2024, 2023 and 2022 were as follows:
Year Ended December 31,
202420232022
(in thousands, except per share data)
Weighted average grant-date fair value of restricted stock units granted$10.39 $13.72 $18.06 
Total fair value of restricted stock units and restricted shares vested$3,257 $2,991 $3,307 
Schedule of Outstanding Performance Stock Units
A summary of the outstanding PSUs as of December 31, 2023 and changes during the year ended December 31, 2024 is as follows:
Performance Stock Units
NumberWeighted Average Grant Date Fair Value
(in thousands)
December 31, 2023175 $21.52 
Granted118 $11.85 
Vested— $— 
Forfeited(35)$34.52 
December 31, 2024258 $15.31 
Schedule of ESPP Annual Offerings
The following table summarizes information about the Company’s ESPP annual offerings for the years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
202420232022
(in thousands, except per share data)
Common shares purchased88 95 95 
Per common share purchase price$8.81 $8.81 $10.20 
Schedule of Options Granted Estimated Expense Valuation Assumptions
The expense associated with the options granted under the ESPP during the year ended December 31, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions:
Year Ended December 31,
20242023
Risk-free interest rate4.8%4.8%
Weighted average expected life (years)1.01.0
Expected volatility37.1%42.9%
Dividend yield—%7.1%
Schedule of Information Of SERP
The following table summarizes information about the SERP during the plan years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
 202420232022
(in thousands)
SERP expense 1
$579 $533 $486 
Treasury shares issued to fund SERP expense2
49 50 40 
Year end SERP trust account balance3
$51,138 $42,313 $35,111 
Unrealized gain (loss) recorded in SERP liability account$8,241 $6,684 $(9,178)
1.Both the SERP match and the deferrals are included in the selling, general and administrative caption in the Consolidated Statements of Comprehensive Income.
2.Shares related to the SERP match for each year are funded at the beginning of the subsequent year.
3.SERP trust account investments are recorded at their fair value which is based on quoted market prices. Differences between such amounts in the table above and the deferred compensation funding asset reported on the Company’s Consolidated Balance Sheets represent the value of Company common stock held in the Plan participants’ trust accounts and reported by the Company as treasury stock in the Company’s Consolidated Balance Sheets.
v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes
The following table summarizes the provision for income taxes:
Year Ended December 31,
202420232022
(amounts in thousands)
Current:
Federal$12,275 $13,728 $3,022 
State4,139 5,762 2,381 
$16,414 $19,490 $5,403 
Deferred:
Federal$(2,304)$(4,183)$4,163 
State(640)(637)744 
$(2,944)$(4,820)$4,907 
Tax provision$13,470 $14,670 $10,310 
Schedule of Significant Components of Federal and State Deferred Tax Assets and Liabilities
Significant components of the Company’s federal and state deferred tax asset and liability balances were as follows:
 Year Ended December 31,
 20242023
(in thousands)
Deferred tax assets:
Allowance for doubtful accounts$25,138 $22,788 
Deferred compensation9,159 9,048 
Accrued insurance claims5,277 5,580 
Non-deductible reserves497 169 
Lease liabilities4,214 4,765 
Share based compensation3,312 2,988 
Other3,275 2,418 
$50,872 $47,756 
Deferred tax liabilities:
Expensing of housekeeping supplies$(2,174)$(2,351)
Amortization of goodwill and intangibles(3,861)(3,000)
Depreciation of property and equipment(1,664)(1,688)
Lease right-of-use assets(4,048)(4,571)
Other(955)(920)
$(12,702)$(12,530)
Net deferred tax assets$38,170 $35,226 
Schedule of Reconciliation of The Provision for Income Taxes
The table below provides a reconciliation between the tax expense computed by applying the statutory federal income tax rate to income before income taxes and the provision for income taxes:
 Year Ended December 31,
 202420232022
(in thousands)
Income tax expense computed at statutory rate$11,118 $11,182 $9,356 
Increases (decreases) resulting from:
State income taxes, net of federal tax benefit2,631 4,153 2,594 
Federal jobs credits(1,914)(2,014)(2,571)
Tax exempt interest(306)(348)(308)
Share-based compensation1,722 1,610 1,250 
Fines and penalties18 55 4 
Other, net201 32 (15)
Income tax expense$13,470 $14,670 $10,310 
v3.25.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information
The following tables provide profit information disaggregated by the Company’s reportable segments for each of the years ended December 31, 2024, 2023, and 2022:

Year Ended December 31, 2024
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$765,368 $950,314 $1,715,682 
Significant Segment Expenses
Labor and labor-related1
600,198 537,446 1,137,644 
Food, chemicals and supplies56,504 308,859 365,363 
Bad debt expense14,101 32,659 46,760 
Depreciation and amortization expense3,701 2,856 6,557 
Other segment items2
15,454 22,473 37,927 
Segment profit$75,410 $46,021 $121,431 
Segment margin9.9 %4.8 %
Unallocated expenses (income)
Corporate expenses3
$68,160 
Gain on deferred compensation plan investments8,241 
Other (income), net(14,349)
Interest expense6,438 
Income before income taxes$52,941 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.
Year Ended December 31, 2023
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$766,651 $904,738 $1,671,389 
Significant Segment Expenses
Labor and labor-related1
599,881 522,052 1,121,933 
Food, chemicals and supplies58,627 294,690 353,317 
Bad debt expense17,557 18,046 35,603 
Depreciation and amortization expense3,664 3,779 7,443 
Other segment items2
14,907 21,446 36,353 
Segment profit$72,015 $44,725 $116,740 
Segment margin9.4 %4.9 %
Unallocated expenses (income)
Corporate expenses3
$62,082 
Gain on deferred compensation plan investments6,684 
Other (income), net(12,938)
Interest expense7,856 
Income before income taxes$53,056 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.

Year Ended December 31, 2022
HousekeepingDietaryTotal
(in thousands, except for percentages)
Revenues$795,687 $894,489 $1,690,176 
Significant Segment Expenses
Labor and labor-related1
621,469 534,786 1,156,255 
Food, chemicals and supplies63,300 288,975 352,275 
Bad debt expense11,823 20,146 31,969 
Depreciation and amortization4,040 4,528 8,568 
Other segment items2
14,427 19,675 34,102 
Segment profit$80,628 $26,379 $107,007 
Segment margin10.1 %2.9 %
Unallocated expenses (income)
Corporate expenses3
$63,218 
Loss on deferred compensation plan investments(9,178)
Other expense, net5,427 
Interest expense2,987 
Income before income taxes$44,553 
1.Includes direct labor costs, field management costs (including certain costs included in selling, general and administrative expense), employer taxes, workers' compensation and general liability insurance.
2.Includes expenses for technology, employment advertising, travel & entertainment, professional services and various other less significant expense items.
3.Represents selling, general and administrative expense less the amounts allocated to segments for labor and benefits.
The following table provides capital expenditures disaggregated by the Company’s reportable segments for each of the years ended December 31, 2024, 2023, and 2022:

Year Ended December 31,
202420232022
(in thousands)
Capital expenditures
Housekeeping$5,166 $4,684 $4,412 
Dietary936 494 499 
Corporate overhead234 228 299 
Consolidated$6,336 $5,406 $5,210 
v3.25.0.1
Basic Earnings Per Common Share (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares The table below reconciles the weighted-average basic and diluted common shares outstanding for 2024, 2023 and 2022:
Year Ended December 31,
202420232022
Numerator for basic and diluted earnings per share:
Net income$39,471 $38,386 $34,243 
Denominator:
Weighted average number of common shares outstanding - basic73,754 74,288 74,336 
Effect of dilutive securities1
234 52 15 
Weighted average number of common shares outstanding - diluted73,988 74,340 74,351 
Basic earnings per share:$0.54 $0.52 $0.46 
Diluted earnings per share:$0.53 $0.52 $0.46 
1.Certain outstanding equity awards are anti-dilutive and therefore were excluded from the calculation of the weighted-average number of diluted common shares outstanding.
Schedule Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans
Anti-dilutive outstanding equity awards under share-based compensation plans were as follows:

Year Ended December 31,
202420232022
(in thousands)
Anti-dilutive equity awards2,788 3,228 3,203 
v3.25.0.1
Description of Business and Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2024
USD ($)
institution
segment
shares
Dec. 31, 2023
USD ($)
institution
shares
Dec. 31, 2022
USD ($)
Jun. 18, 2024
shares
Jun. 17, 2024
shares
Schedule of Accounting Policies [Line Items]          
Number of reportable segments | segment 2        
Marketable securities $ 75,640,000 $ 93,131,000      
Unrealized gains (losses) from marketable securities $ (500,000) 1,600,000 $ (7,500,000)    
Inventory supplies amortization period 24 months        
Depreciation $ 11,900,000 10,500,000 10,500,000    
Impairment of long-lived assets $ 0 $ 0 0    
Common stock, authorized (in shares) | shares 200,000,000 100,000,000   200,000,000 100,000,000
Number of financial institutions holding cash and cash equivalents and marketable securities | institution 2 2      
Revenue $ 1,715,682,000 $ 1,671,389,000 1,690,176,000    
Accounts receivable 330,907,000 344,864,000 308,624,000    
Notes receivable $ 41,054,000 $ 24,832,000 $ 32,609,000    
Services provided          
Schedule of Accounting Policies [Line Items]          
Payment terms The Company’s payment terms with customers for services provided are defined within each customer’s service agreement and range from prepaid to 120 days.        
Promissory notes          
Schedule of Accounting Policies [Line Items]          
Payment terms The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses.        
Sysco | Products and other items | Vendor          
Schedule of Accounting Policies [Line Items]          
Concentration percentage 50.00%        
Genesis          
Schedule of Accounting Policies [Line Items]          
Accounts receivable $ 46,100,000        
Notes receivable $ 21,900,000        
Genesis | Consolidated revenues | Significant Customers          
Schedule of Accounting Policies [Line Items]          
Concentration percentage 8.70% 10.90% 10.00%    
Revenue $ 148,900,000 $ 181,400,000 $ 169,100,000    
Health Care Consulting Company          
Schedule of Accounting Policies [Line Items]          
Equity method investments $ 2,800,000        
Equity method investment, ownership percentage 25.00%        
Computer hardware and software          
Schedule of Accounting Policies [Line Items]          
Property plant and equipment, useful life 5 years        
Minimum          
Schedule of Accounting Policies [Line Items]          
Cancellation notice period 30 days        
Initial period preceding cancellation notice 60 days        
Minimum | Housekeeping and Dietary equipment          
Schedule of Accounting Policies [Line Items]          
Property plant and equipment, useful life 3 years        
Minimum | Vehicles          
Schedule of Accounting Policies [Line Items]          
Property plant and equipment, useful life 5 years        
Maximum          
Schedule of Accounting Policies [Line Items]          
Cancellation notice period 90 days        
Initial period preceding cancellation notice 120 days        
Maximum | Housekeeping and Dietary equipment          
Schedule of Accounting Policies [Line Items]          
Property plant and equipment, useful life 5 years        
Maximum | Vehicles          
Schedule of Accounting Policies [Line Items]          
Property plant and equipment, useful life 10 years        
v3.25.0.1
Description of Business and Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash and cash equivalents $ 56,776 $ 54,330 $ 26,279  
Restricted cash equivalents 3,355 0 0  
Total cash and cash equivalents and restricted cash equivalents $ 60,131 $ 54,330 $ 26,279 $ 70,794
v3.25.0.1
Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenue $ 1,715,682 $ 1,671,389 $ 1,690,176
Reduction in revenue   13,800  
Description of timing The Company’s contracts with customers typically provide for an initial term with renewable service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.    
Customers Pending Contract      
Disaggregation of Revenue [Line Items]      
Contract liabilities $ 200 100 300
Customer Prepayment      
Disaggregation of Revenue [Line Items]      
Contract liabilities 4,000 3,200 3,100
Revenue recognized $ 1,900 1,800  
Minimum      
Disaggregation of Revenue [Line Items]      
Cancellation notice period 30 days    
Initial period preceding cancellation notice 60 days    
Maximum      
Disaggregation of Revenue [Line Items]      
Cancellation notice period 90 days    
Initial period preceding cancellation notice 120 days    
Housekeeping      
Disaggregation of Revenue [Line Items]      
Revenue $ 765,400 766,700 795,700
Dietary      
Disaggregation of Revenue [Line Items]      
Revenue $ 950,300 $ 904,700 $ 894,500
v3.25.0.1
Accounts and Notes Receivable - Accounts and Notes Receivable (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Short-term      
Accounts receivable $ 418,427 $ 425,681 $ 375,225
Allowance for doubtful accounts, accounts receivable (87,520) (80,817) (66,601)
Total net accounts receivable 330,907 344,864 308,624
Notes receivable — short–term portion 61,801 45,078 31,744
Allowance for doubtful accounts, notes receivable — short–term portion (10,372) (6,433) (3,591)
Total net notes receivable — short–term portion 51,429 38,645 28,153
Long-term      
Notes receivable 43,944 29,281 35,882
Allowance for doubtful accounts (2,890) (4,449) (3,273)
Total net long-term notes receivable 41,054 24,832 32,609
Total net accounts and notes receivable $ 423,390 $ 408,341 $ 369,386
v3.25.0.1
Accounts and Notes Receivable - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Receivables [Abstract]    
Face value notes receivable with imputed interest $ 39.7 $ 7.6
Discounted value of notes receivable with imputed interest $ 35.9 $ 6.6
Effective interest rate 6.90% 8.00%
v3.25.0.1
Allowance for Doubtful Accounts - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
note
Dec. 31, 2023
USD ($)
note
Dec. 31, 2022
USD ($)
Financing Receivable, Allowance for Credit Loss [Line Items]      
Interest income $ 2,800 $ 2,800 $ 1,100
Accounts receivable, credit loss expense (reversal) $ 40,103 $ 29,095  
Number of tiers receivable | note 3 3  
LaVie Care Centers, LLC      
Financing Receivable, Allowance for Credit Loss [Line Items]      
Accounts receivable, credit loss expense (reversal) $ 17,600    
v3.25.0.1
Allowance for Doubtful Accounts - Notes Receivable Disaggregated by Vintage Year (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Current-period gross write-offs    
Current fiscal year $ 0 $ 0
Year two 742 189
Year three 483 0
Year four 3,024 0
Year five 0 50
Prior 26 2,253
Current-period gross write-offs 4,275 2,492
Current-period recoveries    
Current fiscal year 0 0
Year two 0 0
Year three 0 0
Year four 0 0
Year five 0 0
Prior 0 0
Current-period recoveries 0 0
Current-period net write-offs    
Current fiscal year 0 0
Year two 742 189
Year three 483 0
Year four 3,024 0
Year five 0 50
Prior 26 2,253
Current-period net write-offs 4,275 2,492
Standard notes receivable    
Financing Receivable, Credit Quality Indicator [Line Items]    
Current fiscal year 53,592 18,175
Year two 7,282 25,505
Year three 15,743 855
Year four 0 1,529
Year five 0 3
Prior 0 21,033
Total 76,617 67,100
Current-period net write-offs    
Current-period net write-offs 0 1,646
Delinquent notes receivable    
Financing Receivable, Credit Quality Indicator [Line Items]    
Current fiscal year 499  
Year two 1,055  
Year three 1,942  
Year four 671  
Year five 0  
Prior 21,933  
Total 26,100  
Current-period net write-offs    
Current-period net write-offs 1,252  
Elevated risk notes receivable    
Financing Receivable, Credit Quality Indicator [Line Items]    
Current fiscal year 0 0
Year two 1,537 0
Year three 0 7,259
Year four 0 0
Year five 1,491 0
Prior 0 0
Total 3,028 7,259
Current-period net write-offs    
Current-period net write-offs $ 3,023 $ 846
v3.25.0.1
Allowance for Doubtful Accounts - Age Analysis of Past-Due Note Receivable (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Total    
Financing Receivable, Past Due [Line Items]    
Notes Receivable $ 27,615 $ 17,704
0-90 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 1,128 4,420
91 - 180 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 907 5,421
Greater than 181 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 25,580 7,863
Standard notes receivable    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 76,617 67,100
Standard notes receivable | Total    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 142 15,617
Standard notes receivable | 0-90 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 142 3,851
Standard notes receivable | 91 - 180 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 0 4,852
Standard notes receivable | Greater than 181 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 0 6,914
Delinquent notes receivable    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 26,100  
Delinquent notes receivable | Total    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 24,594  
Delinquent notes receivable | 0-90 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 761  
Delinquent notes receivable | 91 - 180 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 682  
Delinquent notes receivable | Greater than 181 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 23,151  
Elevated risk notes receivable    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 3,028 7,259
Elevated risk notes receivable | Total    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 2,879 2,087
Elevated risk notes receivable | 0-90 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 225 569
Elevated risk notes receivable | 91 - 180 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable 225 569
Elevated risk notes receivable | Greater than 181 Days    
Financing Receivable, Past Due [Line Items]    
Notes Receivable $ 2,429 $ 949
v3.25.0.1
Allowance for Doubtful Accounts - Allowance for doubtful accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accounts receivable      
Accounts receivable, Allowance for doubtful accounts, beginning balance $ 80,819 $ 66,601  
Reclassifications 0    
Write-Offs (33,402) (14,877)  
Bad Debt Expense 40,103 29,095  
Accounts receivable, Allowance for doubtful accounts, ending balance 87,520 80,819 $ 66,601
Notes receivable      
Financing receivable reserves, beginning balance 10,880 6,863  
Reclassifications 0    
Write-Offs (4,275) (2,492)  
Bad Debt Expense 6,657 6,509  
Financing receivable reserves, ending balance 13,262 10,880 6,863
Accounts and Financing Receivable      
Total accounts and notes receivable, beginning balance 91,699 73,464  
Reclassifications 0    
Write-Offs (37,677) (17,369)  
Bad Debt Expense 46,760 35,604 31,969
Total accounts and notes receivable, ending balance 100,782 91,699 73,464
Accounts receivable, allowance for credit loss, recovery 100 200  
Standard notes receivable      
Notes receivable      
Financing receivable reserves, beginning balance 6,125 6,052  
Reclassifications (2,615)    
Write-Offs 0 (1,646)  
Bad Debt Expense 1,586 1,719  
Financing receivable reserves, ending balance 5,096 6,125 6,052
Delinquent notes receivable      
Notes receivable      
Financing receivable reserves, beginning balance 0    
Reclassifications 2,615    
Write-Offs (1,252)    
Bad Debt Expense 4,663    
Financing receivable reserves, ending balance 6,026 0  
Elevated risk notes receivable      
Notes receivable      
Financing receivable reserves, beginning balance 4,755 811  
Reclassifications 0    
Write-Offs (3,023) (846)  
Bad Debt Expense 408 4,790  
Financing receivable reserves, ending balance $ 2,140 $ 4,755 $ 811
v3.25.0.1
Changes in Accumulated Other Comprehensive Loss by Component - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accumulated other comprehensive income      
Accumulated other comprehensive (loss) income — beginning balance $ 456,616 $ 418,279 $ 445,171
Other comprehensive (loss) income before reclassifications (753) 1,624 (7,505)
Losses reclassified from other comprehensive (loss) income 280 9 28
Net current period other comprehensive (loss) income (473) 1,633 (7,477)
Accumulated other comprehensive loss — ending balance 499,927 456,616 418,279
Realized losses (400) (100) (100)
Changes in other comprehensive (loss) income, tax benefit (expense) 100 (400) 2,000
Accumulated Other Comprehensive (Loss) Income, net of Taxes      
Accumulated other comprehensive income      
Accumulated other comprehensive (loss) income — beginning balance (1,844) (3,477) 4,000
Accumulated other comprehensive loss — ending balance $ (2,317) $ (1,844) $ (3,477)
v3.25.0.1
Changes in Accumulated Other Comprehensive Loss by Component - Reclassification Adjustments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Losses from the sale of available-for-sale securities $ 14,349 $ 12,938 $ (5,427)
Tax benefit (13,470) (14,670) (10,310)
Net loss reclassified from accumulated other comprehensive income 39,471 38,386 34,243
Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Net loss reclassified from accumulated other comprehensive income (280) (9) (28)
Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income | Realized Gains (Losses) on Sale of Available-for-sale Securities      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Losses from the sale of available-for-sale securities (355) (12) (37)
Tax benefit $ 75 $ 3 $ 9
v3.25.0.1
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Total property and equipment, net Total property and equipment, net
Operating lease — right-of-use assets $ 29,669 $ 27,099
Total property and equipment, at cost 55,821 50,803
Less accumulated depreciation 27,623 22,029
Total property and equipment, net 28,198 28,774
Accumulated depreciation on operating lease right-of-use assets 13,200 9,400
Housekeeping and Dietary equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 17,052 15,764
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 8,196 6,870
Other    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 904 $ 1,070
v3.25.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]      
Depreciation $ 11.9 $ 10.5 $ 10.5
ROU assets depreciation 7.8 6.4 6.1
Accrued purchases of property and equipment $ 0.5 $ 0.7 $ 0.3
v3.25.0.1
Leases - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Lessee, Lease, Description [Line Items]    
Termination option 1 year  
Short-term lease obligation $ 8.4 $ 7.4
Other Accrued Liability, Current, Statement of Financial Position [Extensible List] Other Accrued Liabilities, Current Other Accrued Liabilities, Current
ROU assets and lease liabilities reduction due to cancellation $ 0.8 $ 2.7
Minimum    
Lessee, Lease, Description [Line Items]    
Remaining lease term 1 year  
Maximum    
Lessee, Lease, Description [Line Items]    
Remaining lease term 5 years  
v3.25.0.1
Leases - Components of Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Lease cost      
Operating lease cost $ 7,799 $ 6,400 $ 5,673
Short-term lease cost 883 1,037 1,265
Variable lease cost 1,609 1,952 857
Total lease cost 10,291 9,389 7,795
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from operating leases 8,125 6,808 6,385
ROU Assets obtained in exchange for lease obligations $ 3,721 $ 6,064 $ 1,650
Weighted-average remaining lease term — operating leases 2 years 7 months 6 days 3 years 3 months 18 days 4 years 2 months 12 days
Weighted-average discount rate — operating leases 6.30% 6.60% 4.40%
v3.25.0.1
Leases - Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Leases [Abstract]  
2025 $ 8,420
2026 5,746
2027 2,264
2028 1,389
2029 116
Thereafter 0
Total minimum lease payments 17,935
Less: imputed lease payments 1,480
Present value of lease liabilities $ 16,455
v3.25.0.1
Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]      
Impairment of goodwill $ 0    
Amortization of intangible assets $ 2,700,000 $ 3,800,000 $ 4,900,000
Customer relationships      
Finite-Lived Intangible Assets [Line Items]      
Weighted average useful life (in years) 10 years    
Trade names      
Finite-Lived Intangible Assets [Line Items]      
Weighted average useful life (in years) 13 years    
Patents      
Finite-Lived Intangible Assets [Line Items]      
Weighted average useful life (in years) 8 years    
Non-compete agreements      
Finite-Lived Intangible Assets [Line Items]      
Weighted average useful life (in years) 4 years    
v3.25.0.1
Goodwill and Other Intangible Assets - Goodwill by Reportable Segment (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Line Items]    
Goodwill $ 75,529 $ 75,529
Housekeeping    
Goodwill [Line Items]    
Goodwill 42,377 42,377
Dietary    
Goodwill [Line Items]    
Goodwill $ 33,152 $ 33,152
v3.25.0.1
Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Amount $ 48,684 $ 48,684
Accumulated Amortization 39,242 36,557
Total 9,442 12,127
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 45,634 45,634
Accumulated Amortization 38,093 35,718
Total 7,541 9,916
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 1,731 1,731
Accumulated Amortization 466 329
Total 1,265 1,402
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 1,086 1,086
Accumulated Amortization 505 369
Total 581 717
Non-compete agreements    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 233 233
Accumulated Amortization 178 141
Total $ 55 $ 92
v3.25.0.1
Goodwill and Other Intangible Assets - Estimated Amortization Expense For Intangibles Subject To Amortization (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2025 $ 2,685  
2026 2,666  
2027 1,195  
2028 613  
2029 509  
Thereafter 1,774  
Total $ 9,442 $ 12,127
v3.25.0.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes $ (500) $ 1,600 $ (7,500)
Proceeds from available for sale municipal bonds 67,012 1,992 10,386
Realized losses 400 100 100
Realized gains 600 1,100 2,400
Unrealized gains related to equity securities 8,300 6,600  
Unrealized losses related to equity securities     (9,300)
Municipal bonds — non-taxable      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Proceeds from available for sale municipal bonds $ 67,000 2,000 10,400
Realized losses   $ 100 $ 100
v3.25.0.1
Fair Value Measurements - Schedule of Contractual Maturities of Debt Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Total marketable securities, at fair value $ 75,640 $ 93,131
Unrestricted    
Debt Securities, Available-for-Sale [Line Items]    
Maturing in one year or less 653 6,324
Maturing in second year through fifth year 23,341 34,939
Maturing in sixth year through tenth year 13,113 39,309
Maturing after ten years 13,428 12,559
Total marketable securities, at fair value 50,535 93,131
Restricted    
Debt Securities, Available-for-Sale [Line Items]    
Maturing in one year or less 2,474 0
Maturing in second year through fifth year 15,774 0
Maturing in sixth year through tenth year 5,837 0
Maturing after ten years 1,020 0
Total marketable securities, at fair value $ 25,105 $ 0
v3.25.0.1
Fair Value Measurements - Marketable Securities and Deferred Compensation Fund Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities $ 75,640 $ 93,131
Deferred compensation plan 49,639 40,812
Prepaid expenses and other assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 1,500 1,500
Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0  
Restricted marketable securities 0  
Deferred compensation plan 49,177 40,306
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 50,535  
Restricted marketable securities 25,105  
Deferred compensation plan 1,961 2,007
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0  
Restricted marketable securities 0  
Deferred compensation plan 0 0
Municipal bonds — taxable | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0  
Restricted marketable securities 0  
Municipal bonds — taxable | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 9,600  
Restricted marketable securities 9,130  
Municipal bonds — taxable | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0  
Restricted marketable securities 0  
Municipal bonds — non-taxable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   93,131
Municipal bonds — non-taxable | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0 0
Municipal bonds — non-taxable | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 40,935 93,131
Municipal bonds — non-taxable | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0 0
U.S. treasury bonds | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
U.S. treasury bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 7,309  
U.S. treasury bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
U.S. government agency bonds | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
U.S. government agency bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 1,218  
U.S. government agency bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
International fixed income bonds | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
International fixed income bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 652  
International fixed income bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
Corporate bonds | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
Corporate bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 6,796  
Corporate bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 0  
Money Market | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Money Market | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 1,961 2,007
Money Market | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Commodities | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 295 298
Commodities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Commodities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Fixed income | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,417 4,254
Fixed income | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Fixed income | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
International | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,999 4,621
International | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
International | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap blend | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,669 5,053
Large cap blend | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap blend | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap growth | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 18,524 13,886
Large cap growth | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap growth | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap value | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,964 5,964
Large cap value | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Large cap value | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Mid cap blend | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 3,957 3,192
Mid cap blend | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Mid cap blend | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Real estate | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 372 374
Real estate | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Real estate | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Small cap blend | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 2,980 2,664
Small cap blend | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Small cap blend | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 0 0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 50,535  
Restricted marketable securities 25,105  
Deferred compensation plan 51,138 42,313
Carrying Amount | Municipal bonds — taxable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 9,600  
Restricted marketable securities 9,130  
Carrying Amount | Municipal bonds — non-taxable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 40,935 93,131
Carrying Amount | U.S. treasury bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 7,309  
Carrying Amount | U.S. government agency bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 1,218  
Carrying Amount | International fixed income bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 652  
Carrying Amount | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 6,796  
Carrying Amount | Money Market    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 1,961 2,007
Carrying Amount | Commodities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 295 298
Carrying Amount | Fixed income    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,417 4,254
Carrying Amount | International    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,999 4,621
Carrying Amount | Large cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,669 5,053
Carrying Amount | Large cap growth    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 18,524 13,886
Carrying Amount | Large cap value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,964 5,964
Carrying Amount | Mid cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 3,957 3,192
Carrying Amount | Real estate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 372 374
Carrying Amount | Small cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 2,980 2,664
Total Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 50,535  
Restricted marketable securities 25,105  
Deferred compensation plan 51,138 42,313
Total Fair Value | Municipal bonds — taxable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 9,600  
Restricted marketable securities 9,130  
Total Fair Value | Municipal bonds — non-taxable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 40,935 93,131
Total Fair Value | U.S. treasury bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 7,309  
Total Fair Value | U.S. government agency bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 1,218  
Total Fair Value | International fixed income bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 652  
Total Fair Value | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted marketable securities 6,796  
Total Fair Value | Money Market    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 1,961 2,007
Total Fair Value | Commodities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 295 298
Total Fair Value | Fixed income    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,417 4,254
Total Fair Value | International    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 4,999 4,621
Total Fair Value | Large cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,669 5,053
Total Fair Value | Large cap growth    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 18,524 13,886
Total Fair Value | Large cap value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 6,964 5,964
Total Fair Value | Mid cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 3,957 3,192
Total Fair Value | Real estate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan 372 374
Total Fair Value | Small cap blend    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Deferred compensation plan $ 2,980 $ 2,664
v3.25.0.1
Fair Value Measurements - Marketable Debt Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost $ 78,573 $ 95,466
Gross Unrealized Gains 123 387
Gross Unrealized Losses (3,056) (2,722)
Estimated Fair Value 75,640 93,131
Credit Impairment Losses 0 0
Municipal bonds — non-taxable    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost   95,466
Gross Unrealized Gains   387
Gross Unrealized Losses   (2,722)
Estimated Fair Value   93,131
Credit Impairment Losses   0
Unrestricted    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 53,531  
Gross Unrealized Gains 0  
Gross Unrealized Losses (2,996)  
Estimated Fair Value 50,535 93,131
Credit Impairment Losses 0  
Unrestricted | Municipal bonds — taxable    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 10,276  
Gross Unrealized Gains 0  
Gross Unrealized Losses (676)  
Estimated Fair Value 9,600  
Credit Impairment Losses 0  
Unrestricted | Municipal bonds — non-taxable    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 43,255  
Gross Unrealized Gains 0  
Gross Unrealized Losses (2,320)  
Estimated Fair Value 40,935  
Credit Impairment Losses 0  
Restricted    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 25,042  
Gross Unrealized Gains 123  
Gross Unrealized Losses (60)  
Estimated Fair Value 25,105 $ 0
Credit Impairment Losses 0  
Restricted | Municipal bonds — taxable    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 9,131  
Gross Unrealized Gains 40  
Gross Unrealized Losses (41)  
Estimated Fair Value 9,130  
Credit Impairment Losses  
Restricted | U.S. treasury bonds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 7,276  
Gross Unrealized Gains 38  
Gross Unrealized Losses (5)  
Estimated Fair Value 7,309  
Credit Impairment Losses  
Restricted | U.S. government agency bonds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 1,208  
Gross Unrealized Gains 10  
Gross Unrealized Losses 0  
Estimated Fair Value 1,218  
Credit Impairment Losses  
Restricted | International fixed income bonds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 647  
Gross Unrealized Gains 5  
Gross Unrealized Losses 0  
Estimated Fair Value 652  
Credit Impairment Losses  
Restricted | Corporate bonds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]    
Amortized Cost 6,780  
Gross Unrealized Gains 30  
Gross Unrealized Losses (14)  
Estimated Fair Value 6,796  
Credit Impairment Losses  
v3.25.0.1
Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income $ 9,165 $ 8,985 $ 9,214
Total recognized tax deficiency related to share-based compensation (607) (773) (783)
Selling, general and administrative expense      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income 9,086 8,942 9,160
Costs of services provided      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income 79 43 54
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income 708 969 1,253
Restricted stock units and deferred stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income 6,870 6,657 6,972
Performance stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income 1,341 1,210 819
Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total pre-tax share-based compensation expense charged against income $ 246 $ 149 $ 170
v3.25.0.1
Share-Based Compensation - Additional Information (Details)
 12 Months Ended
May 28, 2024
shares
Jan. 03, 2024
shares
May 30, 2023
shares
Dec. 31, 2024
USD ($)
participant
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost | $       $ 16,200,000 $ 16,500,000  
Period of expense of unrecognized compensation cost       2 years 9 months 18 days 2 years 9 months 18 days  
Weighted average grant-date fair value of stock options granted (in dollars per share) | $ / shares       $ 5.06 $ 6.53 $ 4.06
Aggregate intrinsic value of stock options exercised | $           $ 100,000
Fair value of options vested | $       $ 1,000,000 $ 1,300,000 $ 1,800,000
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares       $ 10.39 $ 13.72 $ 18.06
SERP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Percentage of earned income on a pre-tax basis, deferred       25.00%    
Percentage of match participants' deferrals       25.00%    
Percentage of deferral in the form of common stock       15.00%    
Full vest in matching contribution       3 years    
Shares authorized for issuance (in shares)       1,000,000.0    
Common stock reserved for future issuance (in shares)       200,000    
Stock options vested and outstanding (in shares)       400,000    
2020 Omnibus Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Increase in shares authorized under plan (in shares)     2,500,000      
Common stock reserved for future issuance (in shares)       6,700,000    
Shares available for future grant (in shares)       2,400,000    
Maximum term of grants       10 years    
Restricted stock units and deferred stock units            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Restricted stock granted (in shares)       775,000 500,000 400,000
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares       $ 10.39 $ 13.72 $ 18.06
Restricted Stock Units (RSUs)            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Period of expense of unrecognized compensation cost       3 years 1 month 6 days    
Deferred stock units            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Requisite service period for plan participation eligibility       5 years    
Deferred stock units | Non employee director            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost | $       $ 100,000    
Period of expense of unrecognized compensation cost       4 months 24 days    
Restricted stock granted (in shares) 30,000          
Number of participants electing to receive shares | participant       3    
Vesting period 1 year          
Performance stock units            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost | $       $ 1,400,000    
Period of expense of unrecognized compensation cost       1 year 4 months 24 days    
Restricted stock granted (in shares)   100,000   118,000    
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares       $ 11.85    
Vesting period   3 years        
Employee Stock Purchase Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for future grant (in shares)       1,700,000    
Requisite service period for plan participation eligibility       2 years    
Average weekly hours of work       20 hours    
Stock options authorized to issue to employees (in shares)       4,100,000    
Annual earnings withheld to purchase common stock | $       $ 21,250    
Percent of IRS limitation       85.00%    
Maximum fair value of common stock purchased | $       $ 25,000    
ESPP purchase price of common stock, percent of market price       85.00%    
ESPP purchase price of common stock, percent of market price offering period       85.00%    
v3.25.0.1
Share-Based Compensation - Schedule of Stock Options Outstanding (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Number of Shares  
Beginning of period (in shares) | shares 2,438
Granted (in shares) | shares 290
Exercised (in shares) | shares 0
Forfeited (in shares) | shares (1)
Expired (in shares) | shares (199)
Ending of period (in shares) | shares 2,528
Weighted Average Exercise Price  
Beginning of period (in dollars per share) | $ / shares $ 30.43
Granted (in dollars per share) | $ / shares 10.36
Exercised (in dollars per share) | $ / shares 0
Forfeited (in dollars per share) | $ / shares 24.43
Expired (in dollars per share) | $ / shares 29.12
Ending of period (in dollars per share) | $ / shares $ 28.23
v3.25.0.1
Share-Based Compensation - Assumptions for Fair Value of Options Granted (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Risk-free interest rate 3.90% 4.00% 1.50%
Weighted average expected life 7 years 6 years 10 months 24 days 6 years 8 months 12 days
Expected volatility 40.50% 39.50% 36.60%
Dividend yield 0.00% 0.00% 4.60%
v3.25.0.1
Share-Based Compensation - Schedule of Information About Stock Awards (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Outstanding:  
Aggregate intrinsic value $ 400
Weighted average remaining contractual life 4 years 6 months
Exercisable:  
Number of options (in shares) | shares 1,737
Weighted average exercise price (in dollars per share) | $ / shares $ 33.91
Aggregate intrinsic value $ 0
Weighted average remaining contractual life 3 years
v3.25.0.1
Share-Based Compensation - Schedule of Restricted Stock Units and Deferred Stock Units (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Weighted Average Grant Date Fair Value      
Granted (in dollars per share) $ 10.39 $ 13.72 $ 18.06
Restricted stock units and deferred stock units      
Number      
Beginning balance (in shares) 1,102    
Granted (in shares) 775 500 400
Vested (in shares) (298)    
Forfeited (in shares) (63)    
Ending balance (in shares) 1,516 1,102  
Weighted Average Grant Date Fair Value      
Beginning balance (in dollars per share) $ 18.57    
Granted (in dollars per share) 10.39 $ 13.72 $ 18.06
Vested (in dollars per share) 21.68    
Forfeited (in dollars per share) 13.56    
Ending balance (in dollars per share) $ 13.98 $ 18.57  
v3.25.0.1
Share-Based Compensation - Weighted Average Remaining Grant-Date and Total Fair Values (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) $ 10.39 $ 13.72 $ 18.06
Total fair value of restricted stock units and restricted shares vested $ 3,257 $ 2,991 $ 3,307
v3.25.0.1
Share-Based Compensation - Schedule of Outstanding Performance Stock Units (Details) - $ / shares
shares in Thousands
 12 Months Ended
Jan. 03, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Weighted Average Grant Date Fair Value        
Granted (in dollars per share)   $ 10.39 $ 13.72 $ 18.06
Performance stock units        
Number        
Beginning balance (in shares)   175    
Granted (in shares) 100 118    
Vested (in shares)   0    
Forfeited (in shares)   (35)    
Ending balance (in shares)   258 175  
Weighted Average Grant Date Fair Value        
Beginning balance (in dollars per share)   $ 21.52    
Granted (in dollars per share)   11.85    
Vested (in dollars per share)   0    
Forfeited (in dollars per share)   34.52    
Ending balance (in dollars per share)   $ 15.31 $ 21.52  
v3.25.0.1
Share Based Compensation - Schedule of ESPP Annual Offerings (Details) - ESPP - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Common shares purchased (in shares) 88 95 95
Per common share purchase price (in dollars per share) $ 8.81 $ 8.81 $ 10.20
v3.25.0.1
Share-Based Compensation - Assumptions For Employee Stock Purchase Plan (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 3.90% 4.00% 1.50%
Weighted average expected life (years) 7 years 6 years 10 months 24 days 6 years 8 months 12 days
Expected volatility 40.50% 39.50% 36.60%
Dividend yield 0.00% 0.00% 4.60%
ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 4.80% 4.80%  
Weighted average expected life (years) 1 year 1 year  
Expected volatility 37.10% 42.90%  
Dividend yield 0.00% 7.10%  
v3.25.0.1
Share-Based Compensation - Schedule of Information Of SERP (Details) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
SERP expense $ 9,165 $ 8,985 $ 9,214
SERP      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
SERP expense $ 579 $ 533 $ 486
Treasury shares issued to fund SERP expense (in shares) 49 50 40
Year end SERP trust account balance $ 51,138 $ 42,313 $ 35,111
Unrealized gain (loss) recorded in SERP liability account $ 8,241 $ 6,684 $ (9,178)
v3.25.0.1
Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current:      
Federal $ 12,275 $ 13,728 $ 3,022
State 4,139 5,762 2,381
Total 16,414 19,490 5,403
Deferred:      
Federal (2,304) (4,183) 4,163
State (640) (637) 744
Total (2,944) (4,820) 4,907
Tax provision $ 13,470 $ 14,670 $ 10,310
v3.25.0.1
Income Taxes - Schedule of Significant Components of Federal and State Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Allowance for doubtful accounts $ 25,138 $ 22,788
Deferred compensation 9,159 9,048
Accrued insurance claims 5,277 5,580
Non-deductible reserves 497 169
Lease liabilities 4,214 4,765
Share based compensation 3,312 2,988
Other 3,275 2,418
Deferred tax assets 50,872 47,756
Deferred tax liabilities:    
Expensing of housekeeping supplies (2,174) (2,351)
Amortization of goodwill and intangibles (3,861) (3,000)
Depreciation of property and equipment (1,664) (1,688)
Lease right-of-use assets (4,048) (4,571)
Other (955) (920)
Deferred tax liabilities (12,702) (12,530)
Net deferred tax assets $ 38,170 $ 35,226
v3.25.0.1
Income Taxes - Schedule of Reconciliation of The Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Amount [Abstract]      
Income tax expense computed at statutory rate $ 11,118 $ 11,182 $ 9,356
Increases (decreases) resulting from:      
State income taxes, net of federal tax benefit 2,631 4,153 2,594
Federal jobs credits (1,914) (2,014) (2,571)
Tax exempt interest (306) (348) (308)
Share-based compensation 1,722 1,610 1,250
Fines and penalties 18 55 4
Other, net 201 32 (15)
Tax provision $ 13,470 $ 14,670 $ 10,310
v3.25.0.1
Segment Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting [Abstract]      
Number of reportable segments | segment 2    
Segment Reporting Information [Line Items]      
Revenues $ 1,715,682 $ 1,671,389 $ 1,690,176
Significant Segment Expenses      
Bad debt expense 46,760 35,604 31,969
Depreciation and amortization expense 14,585 14,344 15,316
Unallocated expenses (income)      
Corporate expenses 183,060 166,772 140,344
Interest expense 6,438 7,856 2,987
Income before taxes 52,941 53,056 44,553
Capital expenditures 6,336 5,406 5,210
Housekeeping      
Segment Reporting Information [Line Items]      
Revenues 765,400 766,700 795,700
Dietary      
Segment Reporting Information [Line Items]      
Revenues 950,300 904,700 894,500
Reportable Segments      
Segment Reporting Information [Line Items]      
Revenues 1,715,682 1,671,389 1,690,176
Significant Segment Expenses      
Labor and labor-related 1,137,644 1,121,933 1,156,255
Food, chemicals and supplies 365,363 353,317 352,275
Bad debt expense 46,760 35,603 31,969
Depreciation and amortization expense 6,557 7,443 8,568
Other segment items 37,927 36,353 34,102
Segment profit 121,431 116,740 107,007
Reportable Segments | Housekeeping      
Segment Reporting Information [Line Items]      
Revenues 765,368 766,651 795,687
Significant Segment Expenses      
Labor and labor-related 600,198 599,881 621,469
Food, chemicals and supplies 56,504 58,627 63,300
Bad debt expense 14,101 17,557 11,823
Depreciation and amortization expense 3,701 3,664 4,040
Other segment items 15,454 14,907 14,427
Segment profit $ 75,410 $ 72,015 $ 80,628
Segment margin 9.90% 9.40% 10.10%
Unallocated expenses (income)      
Capital expenditures $ 5,166 $ 4,684 $ 4,412
Reportable Segments | Dietary      
Segment Reporting Information [Line Items]      
Revenues 950,314 904,738 894,489
Significant Segment Expenses      
Labor and labor-related 537,446 522,052 534,786
Food, chemicals and supplies 308,859 294,690 288,975
Bad debt expense 32,659 18,046 20,146
Depreciation and amortization expense 2,856 3,779 4,528
Other segment items 22,473 21,446 19,675
Segment profit $ 46,021 $ 44,725 $ 26,379
Segment margin 4.80% 4.90% 2.90%
Unallocated expenses (income)      
Capital expenditures $ 936 $ 494 $ 499
Corporate      
Unallocated expenses (income)      
Corporate expenses 68,160 62,082 63,218
Gain (loss ) on deferred compensation plan investments 8,241 6,684 (9,178)
Other (income), net (14,349) (12,938) 5,427
Interest expense 6,438 7,856 2,987
Income before taxes   53,056 44,553
Capital expenditures $ 234 $ 228 $ 299
v3.25.0.1
Basic Earnings Per Common Share - Schedule of Weighted Average Number of Shares (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Numerator for basic and diluted earnings per share:      
Net income $ 39,471 $ 38,386 $ 34,243
Denominator:      
Weighted average number of common shares outstanding - basic (in shares) 73,754 74,288 74,336
Effect of dilutive securities (in shares) 234 52 15
Weighted average number of common shares outstanding - diluted (in shares) 73,988 74,340 74,351
Basic earnings per share (in dollars per share) $ 0.54 $ 0.52 $ 0.46
Diluted earnings per share (in dollars per share) $ 0.53 $ 0.52 $ 0.46
v3.25.0.1
Basic Earnings Per Common Share - Schedule Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Anti-dilutive equity awards (in shares) 2,788 3,228 3,203
v3.25.0.1
Other Contingencies (Details)
 12 Months Ended
Nov. 22, 2022
USD ($)
Dec. 31, 2024
USD ($)
covenant
Dec. 31, 2023
USD ($)
Short-term Debt [Line Items]      
Bank line of credit   $ 300,000,000.0  
Basis spread on variable rate   1.65%  
Long-term line of credit   $ 25,000,000.0 $ 25,000,000.0
Effective interest rate   7.26%  
Financial covenants | covenant   2  
Reduction of bank line of credit   $ 50,800,000  
Amount available under line of credit   249,200,000  
Standby letters of credit      
Short-term Debt [Line Items]      
Irrevocable standby letter of credit, outstanding   $ 50,800,000  
Revolving Credit Facility | Unsecured Revolving Loan Facility | Line of Credit      
Short-term Debt [Line Items]      
Unsecured revolving loan facility expiration period 5 years    
Accordion feature, higher borrowing capacity option $ 500,000,000    
v3.25.0.1
Other Employee Benefit Plans (Details)
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Maximum percentage of employee contribution 15.00%
v3.25.0.1
Related Party Transactions (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Equity Method Investee  
Related Party Transaction [Line Items]  
Civil monetary penalty $ 0.6
v3.25.0.1
Accrued Insurance Claims (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Percent of liabilities 25.40% 25.30%
Increase (decrease) in self insurance reserve $ (11.6) $ (12.5)
v3.25.0.1
Treasury Stock (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Feb. 14, 2023
Equity [Abstract]      
Number of shares authorized to be repurchased up to (in shares)     7.5
Purchase of treasury stock (in shares) 0.4 1.0  
Total cost inclusive of transaction costs $ 5.0 $ 11.1  
v3.25.0.1
Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning Balance $ 91,699 $ 73,464 $ 65,584
Charged to Costs and Expenses 46,760 35,604 31,969
Deductions 37,677 17,369 24,088
Ending Balance $ 100,782 $ 91,699 $ 73,464